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ABSTRACT
Asthma is a chronic disease whose effects are controlled/ prevented using appropriate
medication. Although benefits of asthma medication is well known, poor medication adherence
among asthma patients has been reported. Medication non-adherence is associated to increased
healthcare costs, unnecessary hospital utilization, readmissions and even death in few cases. The
overarching goal of this research was to evaluate the impact of medication non-adherence on
hospital admissions, and identify key factors that result in medication non-adherence for
Medicaid insured asthma patients.
To achieve these objectives, Correlation analysis, T-tests, Multivariate logistic analysis
and odds ratios were performed. Based on results of the study, the present study did not find
significant relationships between control medication adherence and the different types of hospital
visits (i.e. emergency department visits, inpatient admits, and readmissions). However, patients
with high rescue medication adherence had fewer emergency department visits (p-value=0.0004)
and inpatient admissions (p-value=0.0303). Patients with more than 4 office visits had better
rescue medication adherence, older and low-income patients had higher 30-day readmissions
rate. While, male and low-income patients had emergency visits
Additionally, The two types of insurance coverages (Temporary Assistance for Needy Families
and Supplemental Security Income-Non Dual) were the only significant predictors of control
medication adherence among the factors analyzed (with p-values =0.0001). Asthma patients with
TANF and SSI- Non Dual coverages are less adherent to control medication adherence compared
to other coverages. Also, control and rescue medication adherence was not significantly different
among case managed and non-case managed asthma patients.

ix

CHAPTER 1: INTRODUCTION
1.1 Introduction
In recent times, the healthcare industry has made great strides in the prevention and curing of
disease through science. Prescription medicines and advances in medical treatment are available
to manage chronic and acute conditions. Even though the healthcare industry has been vouching
for proper use of medication, evidence is available on the prevalence of medication nonadherence. Multiple studies have suggested that patients with poor medication adherence
experience poorer health outcomes and often are the most costly members for their insurance
companies. Although asthma medications can not cure asthma they help reduce symptoms and
prevent asthma attacks. Health outcomes of asthma patients can be improved through
pharmacologic interventions by patient or their family and provider (Pedersen, 2011). Subpar or
irregular medication use has been associated with hospitalizations, hospital readmissions,
emergency department visits, office visits and unnecessary utilization of medical resources
(Miller, 1997). Taking the right medicine at the right time in a proper way, as prescribed by the
doctor, is very important for many chronic illnesses, such as asthma.
According to an Asthma fact report published by Centers for disease control (CDC) in
2013, 3,404 deaths, 439,400 hospitalizations, 1.8 million ED visits and 14.2 million office visits
were reported for the year 2010 (Asthma facts, 2013). Hospital admissions, especially
readmissions are costly. Medicare estimated the cost of hospital readmissions to be $17.4 billion
annually (Jencks et al., 2009) and most of these readmissions are preventable. In an attempt to
reduce healthcare costs and readmission rates, the hospital readmission reduction program
(HRRP) under the Affordable Care Act penalizes hospitals with excessive readmission rates
within 30-days of initial discharge. Therefore under this policy, hospitals and care providers are
forced to improve patient care and reduce unplanned 30-day readmissions (Greenwald, 2007).
This readmission program greatly impacts hospital’s financial performance and makes patient
with chronic illnesses, such as asthma, a high risk.
Understanding factors resulting in medication non-adherence is valuable to improve
medication adherence behavior in patients and in turn reduce non-adherence related hospital
readmission of asthma patients. In the literature, research concerning barriers for medication
adherence among asthma is well documented. However, it mainly focuses on identifying risk
factors, and very few studies attempted to look at the bigger picture i.e. determining the influence
of medication adherence on 30-day readmission rates as well as identifying factors affecting
medication non-adherence and appropriate intervention strategies.
The asthma data needed for this study was collected from a healthcare insurance provider
in Louisiana from active members with an insurance enrollment gap of 45 days or less during
January 2015 through December 2016. Medication Possession Ratio (MPR) with variable
duration (first and last medication fill date for each individual patient) was used to measure
medication adherence for this study. MPR was calculated for each class of asthma medication
i.e. Control medication adherence, Rescue medication adherence and overall MPR for both
classes of medication for each individual patient. Variable MPR was calculated as summation of
all days supply divided by the time between the last and first fill date plus the last days supply of
medication MPR. Days supply of the last fill is added to estimate the expiration of supply.
1

This study is divided into two parts. The objective of the first part was to evaluate the
impact of medication adherence on 30 day & 90 day hospital readmissions for asthma among
Medicaid patients in Louisiana. Further, the effect of age, gender, and discontinuation of certain
medications on medication adherence and readmissions will also be evaluated. The next part of
the study focuses on exploring factors influencing medication adherence among asthma patients
and proposing interventions to improve medication adherence behavior.
1.2 Problem Statement
Recent policy changes in healthcare, requires healthcare businesses to have a better
understanding of factors that can reduce their cost and improve health outcomes for their
patients. Research shows that 75% of total healthcare spending is accounted by chronic
conditions such as heart failure, COPD, diabetes, hypertension, asthma and depression (Jack
Meyer, 2013). Patients with chronic conditions avail more healthcare resources such as
emergency visits, hospital admissions, special assistance and multiple expensive medications.
Although most of the chronic conditions can be managed via proper medication regimen and life
style changes, there is a definite gap between physician orders and patients’ compliance.
Previous studies have shown that 10 to 50% of hospital readmissions are considered to be
avoidable (Jencks, 2009). Therefore, in order to reduce avoidable healthcare costs, the focus
needs to be shifted to improve patient health and reduce unnecessary utilization of resources.
Understanding major contributors of medication non-adherence will be a useful resource in
quality improvement and cost reduction efforts (Anika et al., 2014) and in turn reduce expensive
hospitalizations and readmissions.
1.3 Research Objectives
The overarching goal of this research was to evaluate the impact of medication nonadherence on hospital readmission, and identify key factors that result in medication nonadherence for asthma patients. This thesis document comprises two journal papers directed
toward medication non-adherence and hospital readmission trends for asthma patients.
Paper 1: Empirical Study on Medication Adherence and Hospital Readmission for Medicaid
Insured Asthma Patients- this paper focuses on evaluating the effects of medication nonadherence on patient readmission rates for asthmatic patients. Furthermore, it identifies trends
among asthmatic patient’s medication adherence behaviors with respect to scheduled doctor
visits versus emergency visits (e.g. emergency department, hospitalization and readmission).
This paper will be submitted for publication in the Journal of Allergy and Clinical Immunology.
Paper 2: Selection Criteria for Intervention to Improve Medication Adherence for Asthma
Patients - this paper focuses on identifying key factors and barriers of medication non-adherence
among Medicaid insured asthma patients, evaluating the effectiveness of case management
services and recommending effective patient selection criteria for intervention that will improve
medication adherence rates. This paper will be submitted for publication in the International
Journal of Health Care Quality Assurance.

2

1.4 Outline of the thesis
This thesis follows the paper style, and entails an introduction, two journal papers,
conclusion, future work and reference section.
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CHAPTER 2: PAPER #1
“Asthma study on medication adherence and hospital utilization among Medicaid insured
asthma patients”, proposed submission to the Journal of Allergy and Clinical Immunology
2.1 Abstract
Medication adherence is an important indicator of quality in healthcare and non-adherence is
associated with increased healthcare costs, hospitalizations, readmissions and decline in health
outcomes. Despite the availability of medication to control and avoid adverse health situations,
adherence to these medications among asthma patients varies between 40% and 60%, with 80%
and above being the threshold of good medication adherence (Menckeberg et al., 2008). The aim
of this study is to evaluate the effects of medication non-adherence on patient hospital
readmission rates for asthmatic patients in Louisiana, according to their pharmacy records from
their insurance company during the study period of January 2015- December 2016. Furthermore,
the study identifies trends among asthmatic patient’s medication adherence behaviors with
respect to scheduled doctor visits versus emergency visits (e.g. emergency department,
hospitalization and readmission). The present study did not find significant relationships between
control medication adherence and the different types of hospital visits (i.e. emergency
department visits, inpatient admits, and readmissions). However, patients with high rescue
medication adherence had fewer emergency department visits (p-value=0.0004) and inpatient
admissions (p-value=0.0303). Patients with more than 4 office visits had better rescue
medication adherence. Older and low-income patients had higher 30-day readmissions rates.
Similarly, male and low-income patients had emergency visits.
2.2 Introduction
Non-adherence to medications is a persistent problem, in particular for patients with chronic
conditions. Taking medications as prescribed is associated with lower healthcare expenditure,
decline in number of hospitalizations, readmissions and deaths (Claxton, 2012). Medication
adherence is critical for the success of pay-for-performance approach recently adopted by the
U.S. healthcare system. This approach provides financial incentives to hospitals, physicians, and
other health care providers for achieving optimal outcomes for patients, making readmission
within 30 days for the same condition a main concern. Pay-for-performance has become popular
among policy makers and private and public payers, including Medicare and Medicaid. One in
five Medicare patients discharged from hospitals are readmitted to a hospital within 30 days of
initial discharge (Nehi, 2012). Asthma is a common chronic disease affecting 300 million people
across the world (Jindal, 2012) that could result in hospitalizations and readmissions. Most
asthma hospitalizations are considered avoidable, as the symptoms can be prevented and
controlled with the appropriate use of medications, proper asthma management at home and
outpatient care (Mackinon, Flagstad, Peterson, & Mesch-Beatty, 1996). The objective of this
study is to investigate the association between medication adherence and hospital readmissions
among Medicaid insured asthma patients in Louisiana. The study evaluates the medication
adherence and readmission rates (30 day and 90 day) among asthma patients for a 2 years period
(January 2015- December 2016) using pharmacy and healthcare claims data provided by an
insurance company serving Medicaid beneficiaries.
4

2.3 Literature review
2.3.1 Asthma Medication and Current Treatment
Medication is the primary choice for medical interventions in all chronic conditions since these
conditions cannot be cured, but exacerbations can be prevented and controlled. This study
focuses on one chronic condition, asthma. Asthma management focuses on avoiding triggers,
controlling the symptoms and reducing exacerbations- the latter two can be achieved by using
proper medications. Asthma medicines minimize the risk of severe flare-ups and help asthma
patients in leading an active life. Medicines are prescribed depending on age, severity of asthma,
symptoms and side effects. According to National Asthma Education and Prevention Program
(NAEPP), asthma medications are classified as “rescue” or quick relief or short-term
medications, and “control” or preventive or long-term medications (NAEPP, 2007).
Rescue medications are often referred to as “bronchodilators” and are used in case of acute
asthma attacks for quick relief. The effect of rescue medications lasts up to 4 to 6 hours
(Adkinson, 2014). These medications are not recommended to be used very often due to their
reported side effects such as muscle tremor, rapid heartbeat and restlessness (O’Byrne, 2001).
Rescue medications are available in forms of liquids, tablets, capsules, and injections but inhalers
are most commonly prescribed and preferred. There are three classes of rescue medications:
 Short-acting beta- agonists (SABA): Bronchodilator used to relieve symptoms
quickly (e.g. Albuterol)
 Anticholinergics: Bronchodilators used with or instead of SABA (e.g.
Ipratropium)
 Systemic corticosteroids: Drugs used to manage flare-ups and acute asthma
attacks (e.g. Cortisone)
Rescue medications helps stop asthma attacks after they have started; whereas control
medications are used to prevent asthma attacks from starting. Control medications reduce the
swelling and mucus production in airways. They are used on daily basis for patients with
persistent asthma to prevent exacerbations and inflammations. Effects of these medications last
up to 12 hours or more (Adkinson, 2014; (Watts, 2009), and there are different classes:
 Inhaled corticosteroids (ICS): Anti-inflammatory drugs (e.g. Budesonide)
 Long-acting beta-agonists (LABA): Bronchodilator used to open airways (e.g.
Severent)
 Combination inhalers (ICS/LABA): Combination of ICS and LABA (e.g. Advair
and Symbicort)
 Cromolyn sodium and nedocromil: Add on controller medications or alternatives
for inhaled steroids.
 Leukotriene receptor antagonists (LTRAs): Anti-inflammatory drugs (e.g.
Singulair and Zyflo)
 Immunomodulators: Injection used for moderate to severe asthma related to
allergies
 Methylxanthines: Bronchodilator used to prevent symptoms in the night (e.g.
theophylline).
5

Additional treatments also include bronchial thermoplasty and immunotherapy (Dhar & Goshal,
2013).
(a) Bronchial thermoplasty: The U.S. Food and drug Administration (FDA) approved
procedure involving direct application of thermal energy to mass of smooth muscle in
managing severe asthma (Cox et al., 2006).
(b) Immunotherapy: Small doses of substances (to which a person is allergic to) are injected
under the skin of an asthma patient to reduce their response to the allergens and
symptoms overtime (Joint Task force, 2011).
A wide majority of asthma patients are not be able to use bronchial thermoplasty as it is an
expensive procedure and is not covered under government insurance. In addition, there is a lot of
controversy surrounding immunotherapy and using medication to manage exacerbations and
prevent attacks is unanimously agreed upon in the literature.
Asthma medications prescribed vary across ages. Adults are treated with independent medication
(monotherapy), while combination medications (adjunctive medication) are often prescribed for
children and adolescents (NAEPP, 2007). Although, monotherapy with control medications is
most effective in reducing airway inflammations and improving lung function, LABA
monotherapy is not recommended for long-term control of asthma due to increased risk of
asthma deaths (Nelson, 2006). There is conflicting research over which controller medication
should be preferred. The National Asthma Education and Prevention Program (NAEPP)
recommends ICS over other control medication due to reduced exacerbations, fewer
hospitalizations and its superior anti-inflammatory quality compared to other controller
medication, including leukotriene receptor antagonists (LTRAs) (NAEPP, 2007; Strunk, 2006;
O’Byrne, 2006). Although ICS is referred to as the cornerstone for controlling asthma symptoms,
concerns have been raised due to perceived adverse effects experienced by few people. A
retrospective data analysis on outcomes associated with initiation of different controller therapies
among Medicaid asthma population found that LTRAs are more effective in controlling asthma
over ICS (Balakrishnan, 2005). As a part of treatment, asthma patients that cannot be controlled
by using only one control medication are often prescribed combination medication, also known
as adjunctive therapy. Three of the most common choices of combination medication with ICS
are ICS + long-acting beta-agonists (LABA), ICS + LTRA, and ICS + theophylline. ICS +
LABA combination is widely preferred over other combinations among older people and
additional research is required on its effects on children 5-11 years (Watts, 2009). The British
Thoracic Society/ Scottish Intercollegiate Guideline Network (BTS/SIGN) recommended
prescribing ICS in combination with LABA in a single inhaler, to avoid adverse effects with
LABA monotherapy (SIGN, 2012). Complete treatment for asthma includes combination of
long-term medications such as inhaled corticosteroids (ICS) and use of short-acting betaagonists in case of sudden attacks (Mayo Clinic, 2012). In order to find association between
medications and related chances of readmissions, all the drug classes of rescue and controller
medication taken by asthma patients (with an inpatient admission) during the study period are
considered in this study.
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2.3.2 Asthma Management Guidelines
Certain guidelines have been published in order to improve patient health outcomes and
encourage involvement of patients through education and demonstration of the benefits on
following a plan. The National Heart, Lung and Blood Institute (NHLBI) established strategies
through the National Asthma Education and Prevention Program (NAEPP) for diagnosis and
management of asthma in 1991. The practice of these clinical guidelines resulted in fewer
hospitalizations and deaths associated to asthma, as reported on the 2007 Expert Panel Report 3
(EPR-3) (NAEPP, 2007). EPR-3 is a complete report of the best clinical practices in asthma care
focusing on reducing impairment and likelihood of future asthma attacks. The report focuses on
four components of care: a) Assessment and monitoring, b) Patient education, c) Control
environmental factors and comorbid conditions, and d) Medications. Importance of using an
asthma action plan was highlighted in this report. An asthma action plan is developed by the
doctor and helps patient get involved in taking responsibility and self-managing their or their
children’s illness. It is a plan for how and when a medication needs to be taken.
Another asthma treatment strategy that was the basis for many national guidelines is the Global
Initiative for Asthma (GINA). GINA was initiated with a goal of providing information about
asthma management and translating scientific evidence research into improved care. GINA has
published and annually updated its global strategy for asthma management and prevention for
the past 20 years. This strategy emphasizes the patient and doctor partnership as being crucial for
satisfactory health outcomes. While the issue of 2012 placed significant importance on having a
written asthma action plan for self-management of asthma, the 2015 issue recommended targeted
treatment and evidence-based approach to implement interventions effectively. A retrospective
research containing data from three clinical studies, based on parameters derived from GINA
guidelines, showed a positive relationship between the guidelines and improved quality of life
(Bateman, Frith, & Braunstein, 2002).
Both NAEPP and GINA guidelines are a step-wise approach to control asthma. NAEPP has a 6step approach and GINA has 5-Step approach of medications to be used, asthma education and
management of comorbidities. According to both guidelines, low-dose ICS are considered first
for controlling asthma across adults and older people. SABAs are prescribed across all age
groups and severities for quick relief to bronchospasm or exercise induced asthma. Frequent
need for SABA or LABA is an indication for need of increased care, medical attention and
therapy (NAEPP, 2007).
2.3.3 Medication Adherence
Approximately 117 million people in the United States live with at least one of the 10 common
chronic conditions (i.e. hypertension, coronary heart disease, stroke, diabetes, cancer, arthritis,
hepatitis, weak or failing kidneys, current asthma, or chronic obstructive pulmonary disease).
Nearly half of all the adults have at least one illness that requires prescribed medication (Ward at
el., 2012) and 1 in 12 people were reported to have asthma in the year 2009 (CDC, 2011).
A person is said to be ‘adherent’ when they take correct doses of medication at times prescribed
by a physician (Osterberg & Blaschke, 2005). Medication adherence is an umbrella term for
compliance and persistence. It is often defined as “the extent to which a patient’s behavior
corresponds with recommendations from a health care provider” (WHO, 2003). In terms of
medication fills, adherence refers to filling out a medication prescription at the prescribed
7

frequency. Importance of medication adherence and its positive association with improved
healthcare outcomes has been well documented in the literature. A study on patients with
cardiovascular diseases found that high adherence to antihypertensive medications were
associated with higher control of blood pressure compared to low or medium adherence
(Krousel-Wood et al., 2015). One asthma study conducted in Canada looked at the effect of
regular use of inhaled corticosteroids on hospitalizations, and found an overall reduction in
hospitalization rate due to regular use of asthma medication (Suissa, 2002). Medication
adherence is alarmingly lower among chronically ill patients compared to patients with acute
conditions (Cramer, 2003; Jackevicius, 2002). Therefore, different measures are being taken by
health care providers to increase medication adherence and avoid adverse situations, including:
using electronic devices set up with reminders, follow-up telephone calls, case management and
other healthcare services provided for educating patients on positive effects of medication
adherence, robust discharge instructions and primary care provider’s (PCP) emphasis on
medication (Bradley et al., 2012).
2.3.4 Medication Non-adherence
The practice of delaying or entirely failing to fill prescriptions, and taking them as per the
recommendations of a physician is called non-adherence. Approximately one-half of patients in
the United States do not take their medications as prescribed (WHO, 2003). Non-adherence
could be intentional or unintentional and might occur during different stages of their treatment
(Vriijens, 2012). Typically, physician prescribes the minimum doses of medication required to
control asthma based on patient’s condition. Inconsistency in adhering to these medications
might cause exacerbations and mislead physicians from identifying the actual reasons for the loss
of treatment effects. This often results in unnecessary increase of dosage strength or change of
medications (Creer & Bender, 1995). Thus, it’s critical to have a good understanding of the
reasons and magnitude of medication non-adherence, in particular for patients with chronic
diseases such as asthma.
Recent estimation shows that medication non-adherence is attributed to $100-$300 billions of
avoidable costs in the U.S. annually (IMS, 2013). The cost per non-adherent asthma patient per
year ranged from $321 for those who were prescribed ICS monotherapy to $741 for those who
were prescribed a combination of ICS and leukotriene receptor antagonists (Tan et al., 2009).
Medication non-adherence not only affects the patient, it also has severe economic impact and is
a major cause of concern for healthcare providers, organizations and payers alike (Hugtenburg J.
G., Timmers L., Elders P. J., Vervloet M., & L, 2013). Non-adherence to medication has been
related to reemergence of tuberculosis (Bloomm & Murray, 1992), higher viral loads in children
with HIV/ AIDS (Martin et al., 2007), lower quality of life among adolescents receiving liver
transplant (Fredericks et al., 2008), and higher disease-related costs and hospitalizations among
patients with diabetes, hypertension, congestive heart failure and hypercholesterolemia (Sokol,
McGuigan, Verbrugge, & Epstein, 2005). In particular for asthma patients, medication nonadherence has become an area of active interest and poor adherence has been associated to
mortality, increased direct and indirect costs, additional healthcare resource utilization, reduced
quality of life and increased asthma symptoms (Bender, 2004; Harrison, 2003; Horne, 2006;
(Engelkes, Janssens, de Jongste, Sturkenboom, & Verhamme, 2015).
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2.3.5 Non-Adherence to Asthma Medications
Despite of the known benefits of using control medications on a daily basis, low adherence rates
have repeatedly been reported across studies, with ICS adherence ranging from 40% to 60%
(Rand et al., 1995; Breekveldt, 2004). A study on asthma medication adherence and beliefs
conducted in Sweden showed that the mean adherence value for filled prescriptions of general
asthma medications was about 68% and although adherence to combination inhalers was higher
compared to single inhaled corticosteroids; overall adherence to asthma medication was low
(Axelsson, 2015). A study found that filling oral steroids prescriptions among children within 7
days of discharge was 56% (Cooper & Hickson, 2001), and a children’s study in Canada
evaluated the effect of filling inhaled corticosteroids within 3 months of discharge (Blais et al.,
1998). Another observational study of 56,168 in U.S., measured asthma controller medication
adherence using pharmacy refill data and found that non-adherence was associated with higher
asthma medical costs (Tan, 2009). The variable nature of symptoms in asthma (with periods of
no attacks) often encourage non-adherent behavior and overtime leads to unexpected asthma
attacks. Non-adherence to asthma medications among children can cause excessive wheezing
and variability in pulmonary function, limiting daily activities (Bauman, Sallis, Dzewaltowski, &
Owen, 2002), results in exacerbations, deterioration of health, need for excessive urgent care,
hospitalizations and death in some cases.
2.3.6 Medication Adherence Measurement
In order to control their illnesses, patients with chronic conditions take necessary medications
throughout their life. Therefore tracking or measuring medication adherence among chronically
ill yields better results compared to patients with acute illnesses. Currently, there is no gold
standard for measuring medication adherence. Selection of an appropriate method depends on
various factors such as the definition of adherence used, resources available, characteristics being
evaluated, patient population, time assessment, and ethical/ legal considerations in contacting or
interviewing the patient (Banfield, 2015). Medication adherence measures can be divided into
two categories: subjective and objective measures.
2.3.6.1 Subjective Measures of Medication Adherence:

Self-reporting and self-assessment of medication adherence with surveys, questionnaires, and
patient diaries, where patients or their family members (on behalf of children) record daily
medication intake patterns are subjective measures of adherence (Elliott, 2006; Rand & Wise,
1994). Many measurement scales and questionnaires, such as Morisky’s medication adherence
scale (MMAS), Medication adherence rating scale (MARS), and Beliefs about medicines
questionnaire (BMQ) have been developed and validated in the literature. In addition, some
scales are developed to measure medication adherence among specific conditions. Medication
adherence rating scale for asthma (MARSA), is a scale used in clinical practice setting to
evaluate medication taking behaviors and attitudes among asthma patients and ASK20 is a selfreporting tool used to measure and identify barriers for medication adherence among asthma and
COPD patients. Although, subjective methods are cost-effective, they are unreliable and increase
the complexity of research, Patient recall bias issues and possible “Hawthorne effect” i.e.
increase in patient’s medication adherence because of their knowledge of being observed might
produce dubious results.
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2.3.6.2 Objective measures of medication adherence:

Objective measures documented in the literature includes:








Biological assays: Bodily fluids such as serum, urine, blood or saliva is tested to detect
traces of medication. Positive results for the test/ finding traces of medication is not an
indication of adherence, it only confirms that medication was taken before the test. This
method is invasive and gives consistent results only for certain drugs (e.g. theophylline
and cycloporism).
Electronic monitoring devices: Electronic devices equipped with chips are installed in
with inhalers or oral medications to record the time, frequency and doses of medication
taken by the patient. Although this method is widely used, it has been equally criticized
as the devices are expensive, need training to use and patients were found to deliberately
use the device several times shortly before their doctor visits.
Pill counts and canister weights: Pill counts is a simple method where medication
adherence is calculated by counting number of remaining medication and comparing it
with units of medication issued. Weighing the canister or device and calculating the
change in weight is another similar method. These methods are cost effective and simple,
but might overestimate patient’s medication use; since pills can be disposed and inhalers
could be emptied prior to doctor visit.
Pharmacy records: Pharmacy records provide patient’s medication and refill information.
It is a simpler way of collecting medication related information such as drug name, dose,
how many days’ worth of medication was filled by the patient, prescribing doctor and
filling patterns of patient’s (by identifying if the patient was/ was not in possession of
medication or if there were gaps in filling medications over the study period) for target
population or large number of patients at once. Pharmacy information can be obtained
from pharmacy claims data maintained by pharmacies, Insurance and healthcare
providers. Reliability and validity of prescription claims data has been examined by
numerous researchers in the United States This method is cost effective, noninvasive,
simpler and proven to be efficient. However, refill behaviors do not guarantee that
patients are actually taking the medication as prescribed. Various methods of calculating
medication adherence using pharmacy claims records are available. This method requires
data set to be valid, complete and accurate, patients continuous eligibility during the
study is required along with information on changes in insurance plans and any additional
treatment services available to the patients. A number of calculations are available in
literature to report the rate of medication adherence among chronically ill patients. Some
of the most commonly used calculations include Medication possession ratio (MPR),
Cumulative medication gap (CMG) and Proportion of days covered (PDC).

2.3.7 Medication Possession Ratio (MPR)
MPR is calculated as the sum of the days’ supply obtained during the study period divided by
the total number of days in this time period plus the last fills days supply. It has been a go-to
method to calculate medication adherence using claims data in the past. MPR measures
adherence by assessing medication availability and determining skipped or discontinued
medications (Md Redzuan, Lee, & Mohamed Shah, 2014). MPR is used in the literature to
measured variable or fixed periods and they are called variable MPR (VMPR) and Fixed MPR
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(FMPR), respectively. The main difference in the measurement of MPR is in calculating the
denominator. The denominator of VMPR varies for each individual depending on their first and
last fill date while the denominator of FMR is fixed for all study subjects i.e., the number of days
in the study period (e.g. 1 year study period =365 days). Both methods of measurements are
quite popular but the difference in calculating them complicates comparisons across studies
(Kozma, Dickson, Phillips, & Meletiche, 2013).
FMPR =

Sum of the days supply for all claims during the study period
x 100
No. of days in study period

Equation 1. Fixed Medication Possession Ratio formula

VMPR =

Sum of the days supply for all claims during the study period
x 100
Elasped days (inclusive of last prescription)

Equation 2. Variable Medication Possession Ratio formula

MPR approach to adherence measurement has a few drawbacks, such overestimating medication
adherence as it does not address overuse that occurs when patients buy early refills of their
medication causing an overlap and also inflation in the resulting value (Martin et al., 2009).
However, MPR is a widely used and accepted method to measure medication adherence in the
literature and in practice for various illnesses (Patel et al., 2010; Duncan, 2016). Several asthma
studies evaluated medication adherence using MPR. MPR with variable denominator is the
selected method for calculating medication adherence of asthma patients in this study. Various
researchers have considered patients with MPR lower than 80% as non-adherent and more than
80% are to be adherent to medication (Briesacher, 2009).
2.3.8 Hospital Readmissions
Hospital readmissions are defined as multiple hospital stays by the same patient within a
specified time for reason same as related or unrelated to the index admission. Readmissions may
occur due to multiple unexplainable reasons and can be separated by days, weeks, months or
years (Stone &Hoffman, 2010). American Hospital Association (AHA) created a framework
dividing readmissions into 4 types: “(a) planned readmission related to the original admission,
such as placement of ventricular assist device following a heart attack; (b) planned readmission
unrelated to the original admission, such as readmission for a removal of lung tumor discovered
during an admission for heart attack; (c) an unplanned readmission unrelated to the original
admission, such as readmission for a fracture caused by accident following an initial stay of
pneumonia; (d) an unplanned readmission related to the initial admission, such as a surgical site
infection or adverse reaction to a medication” (AHA, 2009). Planned readmissions are not a
cause of concern, they are a part of treatment such as surgery follow up or rehabilitation and
agreed upon by the provider and the patient. Unplanned readmissions related to index admission,
on the other hand accounts to preventable costs, unnecessary resource utilization, patient
dissatisfaction and stress to the family (Jencks, 2009). All hospital readmissions might not be
preventable, many of them could be avoided by providing better care during treatment, and while
transitioning from inpatient stay.
According to a study by University HealthSystem Consortium, most readmissions occur within 7
days of discharge (Arnold, Buys, & Fullas, 2015). Readmissions occurring shortly after hospital
discharge are crucial. They might be a sign of insufficient discharge instructions,
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miscommunication, physician’s inexperience, or patient’s non-adherence to discharge
instructions. There is no a single timeframe for defining hospital readmissions in the literature.
Studies examined readmissions within 15, 30, 60, 90 days or even a year following the discharge
from a hospital (Stone &Hoffman, 2010). This study will focus on the 30 day readmission, given
its criticality in regards to the pay-for-performance approach recently adopted by the U.S.
healthcare system (MedPAC, 2007; CMS, 2012).
In 2007, 17.6% percent of hospital admissions resulted in 30-day readmissions, accounting to
$15 billion in Medicare spending. Medicare Payment Advisory Committee (MedPAC) reported
that 76% of the readmission could have been avoided. Preventable inpatient spending costs
owing to readmissions increased from $15 billion (in 2007) to $17.5 billion by 2010 Medicare
claims (MedPAC, 2007; CMS, 2012). To address this issue and hold hospitals accountable for
high readmissions, Congress and the Centers for Medicare and Medicaid Services (CMS)
established the Affordable Care Act and created a Readmission Reduction Program in the year
2012. Hospitals with excessive readmissions were penalized with one percent reduction in
payments for heart attack, heart failure and pneumonia and the penalty was supposed to increase
to three percent reductions extending to COPD, asthma and select cardiovascular procedures by
the year 2015 (Axon, 2011). As a result, hospitals and care providers were forced to improve
inpatient care, discharge planning coordination, and transitional care from hospital to home
(Greenwald, 2007). Although direct cost of asthma was reported to be $2.2 billion annually with
about 347,000 hospital admissions in the year 2013, limited studies examined 30-day
readmissions among asthma patients, especially among adults (Hasegawa, Gibo, Tsugawa,
Shimada, & Camargo Jr, 2016). Hospital readmissions, especially 30-day readmissions are
considered as indicator of quality. It is used as a pay per performance measure by affordable care
act. Therefore, 30-day readmission of asthma patients across all ages will be evaluated in this
study. Asthma studies in the literature also look at 90-day readmission rates while formulating
interventions. A childhood asthma study, which analyzed inpatient hospitalization, outpatient
and prescription claims records to identify patients who filled asthma discharge medication
(short acting agonist, oral corticosteroid, or inhaled corticosteroid), within 3 days of discharge
from a facility found that filling beta agonists and inhaled steroids was associated with lesser
hospital readmissions (i.e. 90-days) (Kenyon et al., 2015). In addition, the 90-day readmission
will also be analyzed.
2.3.9 Factors Affecting Readmission
Chronic conditions account for many hospitalizations and readmissions due to their persistent
illness. Chronic illnesses require more resources, budget, attention and specialized services (such
as disease management, case management, etc.) for an extended period (WHO, 2002a).
Therefore, readmission’s role as a quality measure has increased during the past decade and
recent studies all over the world examined factors that contribute to patient’s readmission.
A study on childhood asthma based in Auckland, New Zealand found that patient’s age, gender,
number of previous admissions, and severity of the condition were related to readmission during
a 6 month period after discharge (Mitchell, Bland, & Thompson, 1994). Few other studies found
comorbidity, length of stay, lack of documented patient or family education, insurance status,
and marital status are patient-level factors affecting 30-day readmissions (Holloway, Medendorp,
& Bromberg, 1990; Marcantonio et al., 1999). Gender, race, insufficient discharge planning,
drug management and polypharmacy (e.g. use of five or more drugs), have been identified as
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contributory factors with the highest risk of readmission (Kansagara et al., 2011, Viktil et al.,
2007;Wong et al., 2011). This goes to show that reasons for readmission are varied and hence
not all the cases of readmission can be avoided in one specific way.
2.3.10 Link between Readmission and Non-Adherence
Hospital readmissions are known for being indicators of inadequate quality and key contributors
to healthcare costs in the U.S. and around the world. Although many programs have been
implemented to address increasing readmissions and their concurrent healthcare costs, more than
1,400 hospitals were penalized for high readmissions rates in 2012, resulting to costs more than
$280 million (Krauskopf et al., 2013). CMS uses data from three full years to calculate each
hospital’s readmission rate. Therefore, data from the three years, June 2008 to July 2011 was
used for 2013 calculations penalizing 64% of hospitals for diagnosis of heart attack, heart failure
and pneumonia. Similarly, June 2009-July 2012 hospital data was used for calculations in 2014
with 66% of hospitals being penalized for diagnosis of heart attack, heart failure and pneumonia.
COPD, Hip or knee replacement were added to the list in 2015 for data from the years 2010 to
July 2013. 78% of hospitals were penalized in the year. June 2012-July 2015 data were used to
calculate penalties for the year 2016 owing to similar penalty as the year before i.e. 78%
(Boccuti, 2015).
CMS estimated that 11% of hospital readmissions occur due to medication non-adherence and
the resulting costs are estimated to be $100-$289 billion annually (Osterberg & Blaschke, 2005).
A study reported that hospitalizations, readmissions and even death rate were low among patients
that are medication adherent and the risk of these hospitalizations and readmissions among nonadherent patients was 5.4 times high among hypertension patients, 2.8 times high among
dyslipidemia and 1.5 times high among patients with heart diseases (Gwadry-Sridhar et al.
2009). A pediatric asthma study aimed at evaluating factors associated with readmission
conducted a survey regarding asthma knowledge, beliefs, and medication adherence. The study
demonstrated the need to target medication adherence in order to reduce inpatient readmissions
(Auger, Kahn, Davis, & Simmons, 2015). Another study at a university hospital during an 11
month period found that one-third of hospital admissions due to adverse drug events were
medication non-adherence related (McDonnell & Jacobs, 2002). A retrospective cohort analysis
from 12 geographically diverse states on relationship between asthma prescription filling
patterns and hospital readmission rates among patients discharged from an inpatient facility
found that filling of all of three recommended mediations (beta agonists, oral steroids and
inhaled steroids) following discharge was associated with lowest risk of hospital readmission
within 14 days and a statistically significant reduction in readmissions between 15 and 90 days
(Kenyon et al., 2015). One study based in Brazil, assessing the effect of free asthma medications
on hospital admissions showed that the free asthma medications provided by the Brazilian health
system significantly decreased asthma hospitalization rates over a three year period (Comaru,
Pitrez, Friedrich, Silveira, & Pinto, 2016). Among few studies that examined association
between readmissions and specific asthma medications, Saratsafavi et al evaluated controller
medication, reliever medications associated with different inhaled controller treatments as an add
on to systemic corticosteroids, and readmission rate over a period of one year following
discharge among asthma patients (ages 12-25). Taking inhaler medication early after discharge
was associated with reduced readmissions and combination therapy seems to be as effective as
inhaler medication in reducing readmissions and increasing long-term adherence (Sadatsafavi,
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Lynd, De Vera, Zafari, & FitzGerald, 2015). A similar study regarding recurrence risk after an
ED visit or hospitalization and delay in filling asthma controller medication reported increase in
asthma related- ED visits or IP stay when there was a delay in initiation of controller medication
(Sadatsafavi et al., 2015). Treatment with Budesonide inhalation suspension during the first 30
days after inpatient stay and emergency department (ED) visits reduced asthma readmissions or
ED visits. Asthma medication adherence has been associated with reduced exacerbations and
hospitalizations (Camargo, Ramachandran, Ryskina, Lewis, & Legorreta, 2007). Thus, there is
plenty of evidence in the literature on the association between medication adherence and hospital
readmissions. This paper aims at finding the relationship between medication adherence and 30
day readmissions among asthma patients under Medicaid. All classes of asthma medication will
be examined to map the medication taking behavior among asthma patients.
2.3.11 Current Practices Aimed At Reducing Readmissions
A systematic review and meta-analysis aimed at examining the difference in medication
adherence and readmissions between patients who received usual care and an intervention group
found that, the intervention group (patients who received education, self-management and
medication adherence strategies from trained nurses) had lower likelihood of readmission
compared to control subjects (Hyrkas & Wiggins, 2014). Therefore, a number of programs have
been designed to address transitional care needs for patients. Some of the current practices for
readmissions and care transitions include “Project RED”, “Care Transitions Program”, “Project
BOOST”, and “Medicare Demonstrations: Details For Community-Based Care Transition
Program”. Project RED, is short for Project Re-Engineered Discharge developed by a research
group at Boston University Medical Center. The group develops and tests strategies that improve
hospital discharge process, promote safety and reduce readmission rates. RED, consists of 11
components that have been successful in reducing readmissions. This project has demonstrated
reduction in ED visits and readmissions within 30 days of discharge by approximately 30% (Jack
et al., 2009). Care Transition Program is a four week program aimed to improve patient’s
transition from hospital to home. As a part of this program, a Transition Coach educates patients
on self-management using specific tools to reduce readmissions among high-risk Medicare
beneficiaries (CMS, 2007). Project BOOST, stands for Project “Better Outcomes for Older
Adults through Safe Transitions”. This is a care initiate by Society of Hospital Medicine to
improve transitional care among patients. A study to determine the effect of project BOOST on
rehospitalizations and length of stay found that participation in the project appeared to be
associated with decrease in readmission rates. The Community- Based Care Transitions Program
(CCTP) is a program by U.S. Department of Health & Human Services, Centers for Medicare &
Medicaid Services. It aims at reducing hospital readmissions, improving quality of care and
document measurable savings to the Medicare program (CMS fact sheet).
2.4 Research Methodology
The general purpose of this study is to evaluate the effects of medication non-adherence on
patient readmission rates for asthmatic patients. Furthermore, identifies trends among asthmatic
patient’s medication adherence behaviors with respect to scheduled doctor visits versus
emergency visits (e.g. emergency department, hospitalization and readmission).
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2.4.1 Study setting
Data for this study was sourced from a healthcare insurance provider based in Baton Rouge. The
company provides health coverage to Medicaid or LaCHIP qualified people through state’s
Healthy Louisiana program and links Medicaid recipients to primary care providers, pharmacies
and case managers. Institutional Review Board at Louisiana State University reviewed and
approved the study.
2.4.2 Study population
The study population consists of Medicaid patients of all ages with primary or secondary
diagnosis of asthma and insured (with 0 or maximum 45 day enrollment gap from insurance)
during January 1, 2015 to December 31, 2016. International Classification of Diseases, ninth
revision code (ICD 9 codes) 493.XX and tenth revision code (ICD 10 codes) J45.XX, and the list
of asthma medications with 9-digit National Drug Codes (NDC) within each asthma drug class
(Control and rescue medications) were used to identify members with asthma. Patients were
eligible for study inclusion if they met the following criteria: asthma patients admitted at least
once to a hospitals (e.g. inpatient facility) in Louisiana for reason related to asthma; if they had
two or more pharmacy claim for asthma control medication; if they were continuously eligible
and enrolled in health coverage during the study period. Patients who died during the study
period or were discharged to other facility from the hospital during their initial admission, had
missing or invalid claims data, and medical or pharmacy claims for reasons other than or not
related to asthma were excluded from the study. In order to compare the readmission rates an
inpatient admissions data set was collected from a random sample of 1000 non-asthmatic
members to be used as the non-asthmatic group.
2.4.3 Data Source
The insurance company’s databases, MicroStrategy and data warehouse (EDW), were used to
gather the required data for the years 2015 and 2016. These databases capture patient level
clinical utilization, expenditures, and admissions across inpatient, outpatient, and emergency
department, prescription drugs filled, and enrollment into healthcare services (i.e. case
management, disease management or other care services from within the plan). The databases
include present and past members, and dependents insured under them. Data was available
separately for each admits/ visits. Therefore, separate CSV files were gathered from different
reports and linked to the patient through their Medicaid ID, initially. Health Insurance Portability
and Accountability Act of 1996 (HIPPA) policies and guidelines were followed, and all the data
was de-identified before data analysis.
2.4.4 Data collection
Data was collected from different databases called MicroStrategy and data warehouse (EDW)
used by the insurance company. Separate reports on member data, emergency department data,
inpatient stay and prescription medication data was collected. All the reports are linked to one
another through member ID numbers. Figure 1 shows a schematic representation of the data
points available in each of the reports retrieved from the database.
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Figure 1. Schematic of data files provided by the healthcare provider

2.4.5 Measurement of Hospital Readmissions
30-day and 90-day readmissions were calculated from data available in the insurance claims’
records. Readmissions were calculated by counting days between index discharge and
subsequent admission into the hospital and if this value fell between within 30 days and 90 days,
it was considered as 30 or 90-day readmission. Transfer from one facility to other facility is not
considered as hospital readmission. If the patient is discharged from the transferred facility to
home and is admitted back into a hospital within 30 or 90 days, then it is considered as a
readmission.
2.4.6 Measurement of medication fills
Pharmacy claims for the following asthma medications during the study period will be used to
calculate the medication adherence of patients for the two types of medications- Type I- Rescue
Medication: (1) short-acting beta agonists; (2) oral corticosteroids/ systemic corticosteroids; and
Type II- Control Medication: (1) inhaled corticosteroids or a combination inhaled steroid and
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long acting beta agonist; (2) Long-acting beta-agonists; (3) Leukotriene receptor antagonists; (4)
Immunomodulators; (5) Cromolyn sodium and nedocromil; (6) and Methylxanthines.
Medication Possession ratio (MPR)
Control medications are the preferred medication for long-term management of asthma
symptoms, while rescue medications are only used as per need during an asthma attack event.
Studying Control medication adherence on patients with chronic disease like asthma is critical
for better healthcare outcomes. MPR was calculated for control medication and rescue
medications separately for each patient.

MPR =

Total number of days covered
x 100
Last fill date − first fill date + days supply of last fill

The above equation, was used to calculate medication adherence in this study. First, a data file
containing the variables such as patient ID number, National Drug Code (NDC) for drugs, date
of prescription claim, days of supply for prescription claim, and region identifier needed to
calculate MPR for all patients in the study was created and then the equation for calculating
MPR, was followed. Numerator of the formula is the sum of all the days supply for the study
period (2 years for this study) divided by the number of days elapsed (last fill date- first fill date
for each individual) plus days supply of last fill .
SAS 9.4 version and excel were be used to calculate MPR.
2.4.7 Statistical Analysis
The overarching purpose of this study is to evaluate the effects of medication non-adherence on
hospital visit rates for asthma patients. Some of the research questions explored in this study
include:
1. What is the impact of asthma patients’ prescription non-adherence (fail to refill in this
context) on their 30-day and 90-day hospital readmission rate?
2. Are the readmission rates for asthma patients the same as readmissions for patients
without asthma illness (non-asthmatic group)?
3. At the beginning of an asthma treatment, patients are scheduled to visit their doctors
every 2 to 6 weeks and a comprehensive asthma action plan is developed to manage care.
Once the asthma is controlled they can be scheduled to meet the doctors monthly to twice
a year depending on their health and signs of symptoms (NHLBI, 2014). Therefore one of
the questions was: Are 4 visits for the 2 year study period associated to higher levels of
adherence?
4. What is the effect of patients’ demographics on medication adherence and readmission?
The proposition of this study is that prescription non-adherence negatively impacts the
readmission rates on hospitals. In order to better understand the relationship between medication
adherence and different types of patient-doctor interaction including office visits and emergency
visits (i.e. emergency department visits, inpatient stay and hospital readmission rates), the
following hypothesis will be tested:
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o H1: Asthmatic patients with lower level of medication adherence, as measured by
Medication Possession Ratio (MPR), have more emergency visits, including (emergency
department visits, inpatient stay and hospital readmission at various intervals i.e. 30-day
and 90-day).
o H2: Asthmatic patients that attend at least 4 scheduled office visits have higher levels of
medication adherence.
o H3: Patients prescription adherence and emergency visit rates will differ by demographic
groups (age, gender and income level).
o H4: Readmission rates of asthma patients will be significantly different from readmission
rates of non-asthmatic group.
2.4.8 Data Analysis
SAS 9.4 was used for data analysis
1. Descriptive analysis was conducted on the sample to summarize the data collected for the
study. This includes age, gender, income level, and insurance distribution of the study
sample.
2. In order to address H1, a correlation analysis was performed to discover the relationship and
direction of relationship between office visits, emergency visits and prescription nonadherence of asthma patients (control medication and overall medication).
3. In order to address H2, a t-test was performed to see if patients with at least 4 scheduled
office visits have higher levels of medication adherence.
4. In order to address H3, a multiple regression analysis was performed to explore the
relationship between prescription adherence and emergency visits with demographics (age,
gender and income level).
5. In order to address H4, a t-test as well as odds ratio was performed to assess whether the
means of the two groups are statistically different from each other. This analysis was
conducted to understand if readmissions characteristics are similar among asthma patients
and the non-asthmatic group. Lessons learned from this evaluation are discussed and used to
propose effective asthma management guidelines to increase medication adherence.
2.5 Results:
2.5.1 Descriptive Analysis
(a). Sample description of asthma patients (n=687)

Out of the 2085 asthma patients with continuous insurance eligibility for the two-year study
period (January 2015 to December 2016), 687 patients fulfilled the inclusion criteria. A summary
of descriptive statistics for the study population (687 patients) is shown in the tables (2.1- 2.4)
below. The average age was found to be 20 years, with the youngest patient being 1 year old and
the oldest being 65 years old. Most patients (65%, 449) are considered minors, under the age of
18. Approximately 56% of the patients are females (n=384) and 44% are male (n=303), as shown
in Table 2.2. Table 2.3 is related to income distribution shows that 70% of the patients received
median household income of $25,000 to $50,000. From Table 2.4, it is noted that asthma
population for this study are covered under 6 insurance coverages: Temporary assistance for
needy families (TANF) covers 60% of the patients, Medicaid Expansion covers 22% of the
patients, Supplemental security income Non-dual (SSI Non-Dual) covers approximately 12%,
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Foster care covers 2%, Behavioral health covers 1% and Children’s Health Insurance Program
(CHIP) covers 0.29% of the patients. Eligibility criteria for each of the coverages is different and
all of them provide low-cost healthcare coverage to Americans falling under one or more of the
following criteria: people with low income, children, foster care, families, pregnant women,
mental health and substance use disorder, elderly or people with disabilities.
Table 2. 1. Age distribution of asthma patients (n=687)

Table 2. 2. Gender distribution of asthma patients (n=687)

Table 2. 3. Income distribution of asthma patients (n=687)
Income Level
Less than 25K
Between 25K and 50K
Between 51K and 75K
Between 76K and 100K

Number Percent
Cumulative Cumulative
(n)
(%)
Frequency Percent
35
5.09
35
5.09
482
70.16
517
75.25
165
24.02
682
99.27
5
0.73
687
100

Table 2. 4. Insurance distribution of asthma patients (n=687)

(b). Hospital admissions and medication adherence of asthma patients (n=687)

Table 2. 5 summarizes inpatient admissions, Emergency department visits, office visits, 30 day
readmissions and 90 day readmissions for the asthma population. Of 687 asthma patients, 148
patients had inpatient admissions, 263 had emergency visits, 489 had office visits, 25 had 30 day
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readmissions and 24 had 90 day readmissions. During the 2-year period on an average, asthma
patients attended 3 (SD=4.25) office visits, had 2.3 (SD=2.4) emergency department visits, and 2
(SD=1.8) were admitted into the hospital (Inpatient admission). Also, these patients had an
average rate of 1.68 (SD= 1.14) 30-day readmissions and 1.9 (SD=1.8) 90-day readmissions into
the hospital.
Table 2. 5. Description of inpatient, emergency department, office visits, 30 day and 90 day readmissions
for asthmatic population.

Variables
Mean
Standard Error
Standard Deviation
Sample Variance
Minimum
Maximum
Total admissions/visits
Number of patients
Female
Male

Inpatient Emergency
Office
30 day
90 day
admits
Department
Visits
Readmissions Readmissions
(n=148)
(n=263)
(n=489)
(n=25)
(n=24)
1.91
2.35
3.25
1.68
1.96
0.15
0.15
0.19
0.23
0.37
1.82
2.42
4.25
1.14
1.81
3.31
5.86
18.08
1.31
3.26
1
1
1
1
1
14
18
65
5
9
283
618
1587
42
47
148
263
489
25
24
84 (57%)
133 (51%) 255 (52%)
15 (60%)
15(63%)
64 (43%)
130 (49%) 235 (48%)
10(40%)
9(38%)

Medication adherence was measured using variable Medication Possession Ratio (MPR) for
control and rescue medication separately. The inclusion criteria for this study focused on patients
with two or more fills of control medication. Table 2. 6 shows the number and percentage of
asthma patients with control medication adherence, as calculated by their MPR, greater and less
than the threshold of 80% (Briesacher, 2009) across age groups. By inspection, it appears that
younger asthma patients are more adherent to control medication than older patients. The grand
total at the end of the table for the two columns show that 213 (31% are adherent) have control
medication adherence less than 80 and 474 (69% are non-adherent) have MPR more than 80.
Table 2. 6. Control medication adherence for asthma patients across age groups (n=687)

Age groups
0 to 9
10 to 18
19 to 29
30 to 39
40 to 49
50 to 59
60 to 69
Grand Total

Control medication adherence
Less than or equal 80 (non –
More than 80 (adherent) #(%)
adherent) #(%)
90 (13%)
173 (25%)
63 (9%)
123 (18%)
7 (1%)
42 (6%)
12 (2%)
51 (7%)
12 (2%)
40 (6%)
22 (3%)
36 (5%)
6 (1%)
9 (5%)
213 (31%)
474 (69%)
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(c). Sample description of non-asthmatic group

A group of 972 non-asthmatic members were randomly selected i.e., none of these members had
a primary or secondary diagnosis of asthma. These 972 members had continuous Medicaid
eligibility with the same insurance company from January 2015 to December 2016. Of the 972
members only 90 members had 180 inpatient visits for the study period. Therefore 90 nonasthmatic patients were selected to be compared against asthma patients with inpatient
admissions for this study. Reasons for inpatient admissions ranged from general health checkups,
acute illnesses, chronic illnesses, and behavioral health related disorders. Diagnosis description
and count of inpatient admissions for each diagnosis are attached in the Appendix B. 24% of the
members (i.e. 22 members) had 30-day readmissions and 12% of the members (i.e. 11 members)
had 90-day readmissions with minimum number of readmissions being 1 and maximum being 4
readmissions. 8% of the non-asthmatic group members (i.e. 7 members) had both 30 day and 90day readmissions to the hospital.
A cluster analysis was conducted on the non-asthmatic group in order to determine if all the
individuals have the same behavior or to find groups, which are acting differently from the rest.
This analysis was done to determine if was diverse enough to test the non-asthmatic group
against the asthmatic group. Dividing the patients into 4 clusters is associated with an R square
of 82.8 %, which means that the variation of the 4 clusters can explain 82.8% of the entire
variation. Cluster analysis is done to identify homogenous groups that have similar behaviors but
are distinctively different from the other groups. 90 members in the non-asthmatic group are
therefore divided into 4 similar groups. At 4 clusters, the Pseudo F is very high with a value of
138, which confirms the number of clusters found. In addition, the cluster history shows the
components of each cluster (Appendix B)
2.5.2 Correlational analysis for hypothesis #1
A correlation analysis was performed to determine the relation between emergency department
visits, inpatient admits, hospital readmissions (30 day and 90 day) with Control and Rescue
medication adherence, as measured by their MPR.
2.5.2.1 Correlation matrix with control medication:
From table 2. 7., it can be noted that no variable is significantly correlated with Control
medication adherence (MPR), as p-values are all greater than 0.05, but control medication
adherence has a weak negative relationship with emergency department visits (r= -0.03886),
inpatient admits (r= -0.00463) and 90-day readmissions (r= -0.00363). I.e. patient’s adherent to
control medication will have less emergency visits and inpatients admits. Also, there is a weak
positive relationship between control medication adherence and 30-day readmissions (r=
0.03787), i.e. 30 day readmissions increase with increase in control medication adherence.
Table 2. 7. Correlation Matrix for Emergency, inpatient admits, 30 and 90 day readmissions and Control
medication adherence for asthma patients (n=687)
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In addition, results (attached in Appendix C) showed that there’s a strong correlation between the
number of emergency visits and the inpatient admits, between the number of Emergency visits
and the 90 day readmissions, between inpatient admits and the 30 day readmissions, between
inpatient admits and the 90 day readmissions, and between 30 day readmissions and the 90 day
readmissions (p values < 0.05). Which means that any type of hospital utilization results in a
subsequent admission ore readmission to the hospital. We can observe these correlations clearly
in the scatter plots in Appendix B.
2.5.2.2 Correlation matrix with Rescue medication:
Table 2. 8. Correlation Matrix for Emergency, inpatient admits, 30 and 90 day readmissions and Rescue
medication adherence for asthma patients (n=546)

Rescue medication adherence refers to patients that took rescue medications at some point during
the 2 years. Out of 687 asthma patients that took control medications, 546 patients also took
rescue medications as needed. The correlation matrix in table 2. 8., evaluates the relation
between all the hospital visit types and Rescue medication adherence. From table 2.2 it can be
noted that a significant negative relationship exists between emergency department visits (r = 0.14970, p value=0.0004) and inpatient admits (r = -0.09271, p value=0.0303) with Rescue
medication adherence i.e. patients with rescue medication adherence have less number of
emergency department and inpatient admits.
In addition, results (attached in Appendix C) show that there’s a significant strong correlation
between the number of emergency department visits and the inpatient admits, between the
number of Emergency visits and the 90 day readmissions, between inpatient admits and the 30
day readmissions, between inpatient admits and the 90 day readmissions, and between 30 day
readmissions and the 90 day readmissions (p values <0.05). Which means that any type of
hospital utilization results in a subsequent admission ore readmission to the hospital. We can
observe these correlations in scatterplot attached in Appendix C.
2.5.3 T-test for hypothesis #2
In order to test hypothesis #2, evaluating if patients with more than 4 scheduled office visits for 2
years had higher levels of medication adherence, a t-test was run between the two groups (coded
as 0= patients with 0 to 3 office visits, 1= patients with office visits greater than or equal to 4)
with control medication adherence and Rescue medication adherence. From table 2. 9., it can be
noted that variances are equal (p-value is greater than 0.05), therefore we look at the p-value for
“pooled” section. Since the p-value (0.6853) for the pooled section in the table 2. 9., is greater
than 0.05, there is no significant difference. Patients with more than 4 office visits do not have
higher level of control adherence as measured by their MPR.
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Table 2. 9. T- Test for Control medication of patients with/without more than 4 office visits.

Table 2. 10. T- Test for Rescue medication adherence for patients with and without more than 4 office
visits.

From table 2. 10, It can be noted that p-value for pooled section is 0.0063 (less than 0.05).
Therefore patients with more than 4 office visits have higher levels of rescue medication
adherence compared to patients with less than 4 office visits.
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2.5.4 Regression analysis for hypothesis #3
Regression analysis was used in order to explore the relationship between control medication
adherence, type of medical visits (including, inpatient admits, emergency department visits, 30
and 90-day readmissions), and demographics (age, gender, income). The scale of control
medication adherence is if MPR is greater than 80%, patient is considered adherent; and if MPR
is less than 80% patient is considered non-adherent First, the collinearity between the
independent variables age, gender (coded as male=1, female=0) and income level are examined.
No collinearity was found between any of the independent variables (age vs male, age vs
income, and male vs income) (Attached in Appendix D).
Table 2. 11. Regression analysis results for control medication adherence, emergency visits, inpatient
admits, 30 day readmissions and 90 day readmissions vs Age, gender, income.

Regression models were run for control medication adherence, emergency visits, inpatients
admits, and 30 day readmissions and 90 day readmissions vs Age, gender, income. Backward
elimination method was used. The table 2. 11, shows the equation for regression model before
and after backward elimination. Also, from the results of regression analysis (Attached in
Appendix D), it can be concluded that:


Control medication adherence has no relationship with age, gender, and income.
Since the p-values for age (0.5342), gender (0.2785) and median household income
(0.4134) are greater than 0.05 and after backward elimination, no variable is left in the
model. Therefore no relation exists between the dependent and independent variables.



Emergency visits are influenced by gender and income.
P-values for gender (0.0387) and median household income (0.0430) are less than 0.05,
therefore emergency department visits are explained by gender and income. Therefore
men and lower income patients have more emergency visits. All assumptions for
residuals were satisfied.



Inpatient admits have no relationship with age, gender, and income.
Since the p-values for age (0.2008), gender (0.8378) and median household income
(0.5305) are greater than 0.05 and after backward elimination, no variable is left in the
model. Therefore no relation exists between the dependent and independent variables.



30 day readmissions are influenced by age and median household income.

24

P-values for age (0.0616), and median household income (0.0662) are closer to 0.05.
Therefore older patients and lower income patients tend to have more 30 day
readmissions.


90 day readmissions have no relationship with age, gender, and income.
Since the p-values for age (0.7033), gender (0.1488) and median household income
(0.5773) are greater than 0.05 and after backward elimination, no variable is left in the
model. Therefore no relation exists between the dependent and independent variables.

2.5.5 T-test for hypothesis# 4
A T-test was performed in order to test for hypothesis #4, readmission rates of asthma patients
will be significantly different from readmission rates of non-asthmatic group. Asthma patients
and non-asthmatic group patients with readmissions were included in this test and labeled as
asthma patient=1 and non-asthmatic group=0.
For 30 day readmissions:
Table 2. 12., shows that in all cases, the null hypothesis of equal .means and equal variances are
rejected. The p-value (0.0005) <0.05 for Satterthwaite method. Therefore we can conclude that
30-day readmissions among asthma patients and non-asthmatic group are significantly different.
For 90 day readmissions:
Similarly, from table 2. 13., we note that the equality of variances (p value <0.05) is rejected.
Since the equality of variances is rejected, Cochran and Satterthwaite approximations for the pvalue are used here. The p-value is almost equal to 0.05. Therefore, the 90 day readmissions for
the two groups are significantly different.
Table 2. 12. T-test results for 30 day readmissions among asthma patients and non-asthmatic group
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Table 2. 13. T-test results for 90 day readmissions among asthma patients and non-asthmatic group

Odds ratios:
From table 2. 14 and 2. 15 it can be noted that asthma patients have lower chances of 30 day and
90 day readmissions compared to non-asthmatic group ( odds of 30 day readmission is 0.117
times non-asthmatic group [OR 0.117, 95% CI (0.062, 0.218)], odds of 90 day readmissions is
0.260 times the non-asthmatic group [OR 0.260, 95% CI (0.123,0.551)]).
Table 2. 14. Odds ratio of asthma patient and non-asthmatic group for 30 day readmissions
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Table 2. 15. Odds ratio of asthma patient and non-asthmatic group for 30 and 90 day readmissions

2.6 Conclusion and Discussion
The current study explored the relationship between medication adherence and hospital
utilization (inpatient visit, office visit, emergency department visit, 30 day hospital readmission
and 90 day readmission) among Medicaid insured asthma patients. After conducting a statistical
analysis, inpatient admits (p-value= 0.0004) and visits to the emergency department rates (pvalue=0.0303) of asthmatic patients were found to be significantly correlated to rescue
medication adherence. Thus, patients that take their rescue medication tend to have less number
of emergency visits and inpatient admits. Instinctively, this relation seems right. Asthma patients
that understand their medication and use rescue medication in the event of an asthma attack tend
to have lesser emergency department visits, and therefore fewer admissions to the hospital.
In addition, results showed there was a strong positive correlation between the inpatient visits
and 30 day readmissions (r=0.7634, p value <0.05), between inpatient visits and 90 day
readmissions (r=0.7474, p value<0.05) as the r value is closer is to 1. Moderate positive
correlation between 30 day readmissions and 90 day readmissions (r=0.4633, p value<0.05).
Further, from the scatterplots (attached in Appendix b) and p values (Tables 7 and 8) it was
found that emergency department visits were correlated to inpatient admits and 90 day
readmissions. Although lower level of control medication adherence was expected to affect all
types of visits to the hospital, the results showed otherwise. The correlations between the types
of hospital visits were quite expected. As the number of inpatient admits increase the number of
30 and 90 day readmissions also increase and as the number of 30 day readmissions increase, 90
day readmissions increase. This is intuitive, as patients admitted to the hospital often end up
being readmitted. Previous studies reported that one in five Medicare patients discharged from an
inpatient facility end up in the hospital within 30 days (Nehi, 2012). Also, a study to assess
factors that increase 30 day readmissions among asthma patients found that higher frequency of
previous hospital utilizations like emergency department visits and inpatient admissions have
higher likelihood to 30 day readmissions (Gonzalez-Barcala et.al, 2017).
It is a known fact that patients with chronic conditions are often managed at their primary care
physician’s (PCP) office. However, patients might see multiple PCP for their chronic conditions
(Nehi, 2012). This study hypothesized that having more than 4 office visits per year, would
benefit the patient and increase their medication adherence. This number of visits was derived
from the standard of care for asthma patients. The results however showed that patients with
more than 4 office visits do not have higher levels of control medication adherence, a possible
reason for this result, could be the patient’s medical reason for the office visits (i.e., if the visit
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was scheduled or unscheduled because of worsened conditions). This is a limitation of this study,
since the reason for the office visit was not reflected in the insurance data. Knowing the reason
for office visit would help better understand better the relationship among regular scheduled
office visits and patients adherence to their prescribed control medication. Also, in case of
sudden/ seasonal asthma attacks, the trip to the doctor’s office would often result in rescue
medication being prescribed to control asthma. This is in lieu with the result of another t-test for
patients taking rescue medications which showed that patients with more than 4 office visits tend
to have higher levels of rescue medication adherence.
Control medication adherence, emergency visits, inpatient admits, and 30 and 90 day
readmission were checked against age, gender and income, to understand their relationship.
Control medication adherence, inpatient admissions, and 90 day readmissions had r square
values nearly equal to 0 and showed no relationship with age, gender or income level.
Emergency visits were influenced by gender and income level i.e. men and low-income asthma
patients tend to have more Emergency Department visits. Similarly, 30 day readmissions are
influenced by age and median household income, i.e. older and low income patients tend to have
30 day readmissions.
Lastly, 30 day readmissions and 90 day readmissions among asthma patients and non-asthmatic
group were significantly different at 5% significance level. Non-asthmatic group for this study
was a mix of Medicaid insured members without asthma (might or might not have other
illnesses). Although this test does not tell us much, it is interesting to see that 30 day
readmissions among the two groups was significantly different. The chances of 30 day and 90
day readmissions is lower among asthma patients compare to non-asthmatic group.
Previous studies reported that adherence to control medications among asthma patients varies
between 40% and 60%, with 80% and above being the threshold of good medication adherence
(Menckeberg et al., 2008). Average control medication adherence for our population is 82%,
with 474 out of 687 (i.e., 69%) of the patients adhering to their control medications. 283 patients
(41%) had inpatient admissions and 7% of these patients were readmitted into the hospital within
30 and 90 days. The present study did not find any relationship among control medication
adherence and any type of hospital visits (emergency department visits, inpatient admits, office
visits, 30 and 90 day readmissions), while rescue medication adherence was related to
emergency department visits and inpatient admits. Office visits did not seem to improve control
medication adherence but they increased rescue medication adherence among our study
population. Male and low income patients tend to have more emergency visits and older and low
income patients have more 30 day readmissions.
2.6.1 Ethical considerations
IRB committee approval was taken prior to beginning the study and efforts were taken to protect
confidentiality of subjects. Data have been appropriately cleaned and de-identified. Evidence for
reliability and accuracy of data was validated by the data analytics team at the insurance
company.
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2.6.2 Study Limitations and Assumptions
Some of the limitations encountered in the study include possible human error as claims and
other data used in the study is entered and handled by designated person. Demographic
information such as race, ethnicity, marital status etc. and also reasons for office visits were not
available. Discharge instructions given by the doctor after an inpatient admission were not
available and hence it would be hard to track if a medication was discontinued or the strength of
the medication was reduced due to the doctor’s orders or the patient’s negligence. The current
study may not have external validity or generalizability for asthma patients as the study sample
was small and only consisted of patients from one insurance company in the state of Louisiana.
Assumptions made in the study are prescriptions filled are assumed to be prescriptions consumed
and it might not actually be the case.
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CHAPTER 3: PAPER #2
“Selection Criteria for Intervention to Improve Medication Adherence for Medicaid insured
Asthma Patients”, proposed submission to the International Journal of Health Care Quality
Assurance.

3.1 Abstract
The benefits of asthma medications have been well documented, yet poor medication adherence
is often reported among asthma patients. Uncontrolled asthma is associated with a long list of
events such as missed school days; reduced productivity; quality of life; social functioning;
family distress; inflated healthcare costs; hospitalizations; and hospital readmissions (BaenaCagnani et al., 2001). Medication adherence rates are as low as 50% in children and 30%-70%
among adults (Bateman et al., 2008; Milgrom et al., 1996). Asthma results in hundreds of
millions of dollars in healthcare costs – costs that are largely preventable. Medication nonadherence varies across diseases, individuals and across time (Sewitch, 2004), but is prevalent
among asthmatic patients. Poor medication adherence leaves a larger percentage of patients
vulnerable to sudden asthma attacks, hospitalizations and might even result in potential
emergency department visits or hospital readmissions. In order to develop interventions and
improve medication adherence, understanding reasons for non-adherence is important. This
paper focuses on identifying key factors and barriers of medication non-adherence among
Medicaid insured asthma patients in Louisiana and recommends potential interventions. The two
types of insurance coverages (Temporary Assistance for Needy Families and Supplemental
Security Income-Non Dual) were the only significant predictors of control medication adherence
among the factors analyzed (with p-values =0.0001). Asthma patients with TANF and SSI- Non
Dual coverages are less adherent to control medication adherence compared to other coverages.
Also, control and rescue medication adherence was not significantly different among case
managed and non-case managed asthma patients.
3.2 Introduction:
According to the National Health Interview Survey conducted in 2014, there are as many as 24
million people diagnosed with asthma in the United States (CDC). Asthma is a chronic illness
that causes variable degrees of airflow obstruction due to inflammation of airways, increased
mucus secretions, constriction of smooth muscles of bronchi and airway remodeling in the lungs.
Asthma is classified into four-severity levels namely intermittent, mild persistent, moderate
persistent and severe persistent asthma (NAEPP, 1997; Taitel, Allen, & Creer, 1998). Certain
triggers such as irritants, allergens, viral or bacterial infections, exercise or strenuous work,
seasonal changes, and a few others cause sudden asthma attacks or exacerbations among
patients. Triggers for asthma symptoms vary among individuals and they often cause episodes of
wheezing, breathlessness, chest tightness, low oxygen levels, shortness of breath and coughing
(NAEPP, 1997). Therefore there are multiple reasons for an asthma patient to appear at
emergency departments and asthma management is a priority as it results in costly
hospitalizations and even death in some cases.
Although there is unanimous agreement on medications being primary tools to prevent
complications and manage chronic conditions, numerous studies show that medication adherence
42

among chronically ill patients is only 50-60 %. Patients need to follow their medication and get
refills on time to lessen the occurrence of adverse events and to increase their quality of life.
Education/knowledge about illness, targeting high-risk populations, evaluating interventions in
the home environment, and preventive treatment and relief (through medication) from the attacks
are some of the known interventions to effectively keep asthma control in check (CDC, 1996).
This study focuses on finding barriers/ factors affecting medication adherence among asthma
patients, identifying gaps in providing care (such as case management services) and proposing
effective patient selection criteria for intervention to assist in reducing healthcare costs
associated with medication non-adherence.
3.3 Literature Review
3.3.1 Asthma in Louisiana
In Louisiana, an estimated 7.7% (270,261) adults, 18 years of age and older, suffer with asthma
(CDC, 2014). Louisiana Department of Health (DHH) reported that 33 parishes have average
adult asthma prevalence rate higher than 6.7% (2010 asthma prevalence rate) and 11 parishes
(De Soto, E. Feliciana, Richland, Sabine, St. Bernard, St. John the Baptist, Tensas, Vernon,
Washington, W. Baton Rouge, and W. Carroll) have average adult prevalence rates (2006-2010)
that are higher than the 2010 asthma prevalence for the United States (8.8%). Reports indicate
that one in ten (10.7%) Louisiana households with children had at least one child who was
asthmatic (DHH, 2011). According to the factsheet by DHH in 2011, 22.7% of high school
students have reportedly missed more than one school days due to asthma. Due to increasing
prevalence of asthma among children and subsequent missed school days, a law called Louisiana
ACT 145 came into effect in the year 2009, making Louisiana the 49th state in the U.S. to allow
students to carry asthma medications in school. The bill was passed to eliminate the need to
retrieve medications from nurse or offices at school at first signs of asthma attacks.
3.3.2 Asthma Treatment and Care
Expert Panel Reports (EPR) serving as guidelines for diagnosis and management of asthma, are
developed under the National Asthma Education and Prevention Program by National Heart,
Lung, and Blood Institute. Since the nature of asthma symptoms is erratic, it needs continuous
assessment and changes to the patient’s treatment plan. According to the latest Expert Panel
Report (EPR- 3) developed in the year 2007, every person with asthma should have a written
asthma action plan. Typically, an action plan is developed by the doctor and tailored for each
individual patient depending upon the severity and other details of their illness. An asthma action
plan is a daily treatment plan containing measures to be taken in case of asthma attacks or
exacerbations, identifying need to seek doctor/emergency department visit, detailed description
of long-term control treatment, and information on what medication is to be taken at what time
(NAEPP, 2007). Schools, day cares, guardians, family and friends need to know of a child’s
asthma action plan and should be ready in case of emergencies (CDC, 2011).
Treatment goals for asthma are to control symptoms, prevent asthma attacks and reduce
exacerbations. At the beginning of an asthma treatment, patients are scheduled to visit their
doctors every 2 to 6 weeks and a comprehensive asthma action plan is developed to manage care.
Once the asthma is controlled they can be scheduled to meet the doctors once a month to twice a
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year depending on their health and signs of symptoms (NHLBI, 2014). Pulmonary function is
monitored regularly among asthma patients (especially among older patients) using peak flow
meters in order to avoid severe obstruction of airflow (NAEPP, 2007). Peak flow meters are
small hand held devices used to determine the degree of obstruction in the airways and severity
of asthma symptoms (Elana, 2011). Peak flow number shows how well a patient’s lungs are
working while the patient is resting. They are used in emergency departments and clinics to
quickly assess patient’s condition. Patients and their families are educated on usage of Peak flow
meters to be used at home for efficient treatment (Self, 2005).
3.3.3 Asthma Medication
Doctors prescribe asthma medication depending on the type of symptoms some medications are
used to reduce inflammations and swelling in the airways, while others are used to relax the
airways, some medicines are prescribed to be taken even in the absence of symptoms to prevent
any sudden deadly attacks (DHH, 2011). According to the National Asthma Education and
Prevention Program, rescue and control medications are two main categories of asthma
medications. (i) Rescue medication/short-term medication: Acute exacerbations of symptoms
such as coughing, wheezing, chest pain etc. are treated using rescue or short acting medications.
These come in three classes, short-acting beta-agonists, anticholinergics, and systemic
corticosteroids. They are used for instant relief in case of sudden asthma attacks. They are also
called as short-term medication. (ii)Control medication/ long-term medication: Persistent
symptoms such as inflammation or bronchospasms are controlled using control medications. All
asthma control medications were developed to reduce symptoms, improve asthma control,
improve quality of life, prevent exacerbations, and reduce the need for emergency department
usage, hospitalizations and death due to asthma attacks (NAEPP, 2007). There are 8 classes of
control medications: (a) inhaled corticosteroids (ICS), (b) cromolyn sodium and nedocromil, (c)
immunomodulators, (d) systemic corticosteroids, (e) leukotriene receptor antagonists (LTRAs),
(f) 5-liopxygenase inhibitor, (g) long-acting beta-agonists, and (h) methylxanthines. They are
also called long-term medication.
Asthma medications are available in either pill or liquid form to be taken by mouth, injections or
inhalers. Inhalers are most effective and widely used hand held devices used to deliver asthma
medications directly into lungs. Different types of inhalers are available for use. Some of the
inhalers dispense one medication while others are used for combination therapy, meaning they
contain two different medications. Metered dose inhalers (MDI), dry powder inhalers (DPI) and
nebulizers are different types of inhalers used to deliver asthma medication in different ways.
Metered dose inhalers are canisters containing asthma medication. When the inhaler is pushed,
medication is sprayed through it and needs to be breathed in by the patient. Dry powder inhalers
deliver medications in the form of dry powder. These type of medications are hard to breathe in
during an asthma attack. Nebulizers are simple devices where medications are delivered through
a mouthpiece or a mask. They are easier to use and are recommended in case of severe asthma,
as patients can breathe normally while taking the medication (WebMD medical reference, 2015).
In order to lead a normal active life, asthma patients are advised to always have their medication
available and adhere to them as per their prescription.
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3.3.4 Medication adherence and non-adherence:
Chronic illnesses are highly prevalent as about half of all adults in the U.S. (117 million) and
approximately 40% (133 million) of the total population have one or more chronic conditions.
This number is projected to increase to 157 million by the year 2020 (Lancet, 2009). 75% of
healthcare costs are incurred by chronic conditions and four of the most expensive healthcare
conditions are namely: heart diseases, cancer, mental disorders, and pulmonary conditions
(Stanton, 2006). Majority of the patients with chronic diseases are prescribed to follow lifelong
medication in order to control their conditions and avoid complications. Medication adherence is
a key component. It is defined as ‘the extent to which patients follow the instructions given in
their prescribed treatments’ (Haynes et al. 2005). Medication adherence is often studied in terms
of non-adherence, as non-adherence to medication leads to health complications, financial crisis
and poor disease management (Haynes, 2008; Munger et al. 2007). Absence of treatment results
even after prescribing effective medications, led physicians to look into the concept of nonadherence (Rapoff, 1997). Medication non-adherence is taking less medication than prescribed,
or patients not refilling their prescription after the initial fill. About 33% to 69% of medication
related readmissions are due to non-adherence (Osterberg, 2005). Medication adherence is
alarmingly low among patients with chronic conditions and approximately one half of these
patients do not take medications as prescribed by their providers. Poor medication adherence
lead to approximately 125,000 and $100-$300 billion direct and indirect costs every year in the
U.S. (McCarthy, 1998; Mahoney, 2008).
In spite of a detailed asthma action plan, many patients take asthma medications only when they
experience asthma symptoms or attacks and reduce or completely stop using medications during
long symptomless periods. Patients can be completely adherent, completely non-adherent or
have sporadic pattern of adherence. Poor medication adherence is of great concern for physicians
when it comes to medication or dosage selection (Creer & Bender, 1995). A study on asthmatic
patients reported a range from 30% to 70% for adherence to medication, and that adherence to
regular preventive drugs are even lower, about 28% in developing countries (Bender et al., 1997;
Reid et al., 2000; Pearson et al., 1999).
Non-adherence results in increased use of expensive healthcare services which end up costing
more time, money and efforts (such as, emergency care, special care, primary care provider
visits, more medications, hospital services etc.) than treating the original condition. It is also
associated with poor health outcomes, premature deaths and hospital readmissions (Braithwaite
et al., 2013). Research shows that medication non-adherence is related to more than one-third of
medication related hospital visits and 40% of nursing home visits (PhRMA, 2012; APha, 2004).
Therefore, it is important to assess the level of medication adherence among chronically ill
patients to introduce interventions, if needed, to increase medication adherence and health
outcomes. Medication adherence can be measured by:




Subjective measurements include maintaining medication dairies, self-reporting tools,
questionnaires and surveys (Elliott, 2006). Morisky’s scale, is an example for widely
used self-reported measure of adherence, the scale consisted of four questions, and a
negative answer to any of those four questions was considered as non-adherence (George,
2007). Many such self-reported adherence scales have been developed and validated.
Objective measures include pharmacy data, electronic measurement devices, biologic
assays; measurement of testing serum, urine, saliva, and tablet counts, canister weights,
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etc. Biological assays are invasive and do not give long term results, technology based
measurements are ineffective if patients do not use the inhalers properly and pharmacy
data assists in evaluating medication behavior of the patients and insufficient filling of
prescriptions are an indicator of patients who are likely non-adherent but this data could
have discrepancies (Hess, 2006).
In summary, in order to measure medication adherence, an ideal study would include both
objective and subjective methods but in case of time constraints or cost related issues,
objective measure alone can be calculated with consistent pharmacy claims data. This study
will conduct both objective and subjective techniques to measure and understand medication
non-adherence among the studied population.
3.3.5 Factors Affecting Non-adherence
Treatments are only effective when patients adhere to them. Despite the availability, proven
significance in preventing complications, improving health outcomes and reducing asthma
related deaths, non-adherence to medication remains a significant problem. Though numerous
studies on medication non-adherence and factors affecting adherence exists in literature, there is
no consistency in the reported results. A study on adherence and healthcare costs summarized
literature on medication non-adherence by categorizing factors. Categories specified in previous
studies are patient related factors such as demographic (age, gender, income, family size, marital
status), sociocultural (medication beliefs, health literacy, side effects or threats, social standing
and network) and behavioral data (mental illness, stress, substance abuse, cognitive function).
Healthcare provider related factors include communication and provider-patient relations (Iuga,
2014).
A study in Korea on identifying factors that can predict medication adherence among elderly
people found that education level, health-related problems, dosing frequency, satisfaction with
patient counseling and explanation of medication were the main contributors to medication nonadherence (Jin et al., 2016). According to the Harris Interactive 10,000 patient’s survey
conducted in 2002, Among 9,412 patients that participated in the survey, 24% reported
forgetfulness was the main reason for non-adherence followed by 20 % patients reported side
effects, 17 % patients as high drug costs and 14% of respondents reported patient’s perception of
medication effectiveness (Boston Consulting Group, 2003). Number of medications were
recognized as a factor for lower levels of adherence, as requirement of taking multiple
medications at variable intervals in a day is associated with non-adherence among older patients
(Ickovics & Meisier, 1997; Bedell, 2000; Claxton, Cramer, & Pierce, 2001). A cross-sectional
survey of 24,017 adults with asthma, hypertension, diabetes, hyperlipidemia, osteoporosis, or
depression found that 67% agreed that they forget to take medications, 37% of respondents ran
out of medications and 23% reported they were careless about taking medications sometimes
(Gadkari & McHorney, 2010). Adherence to pulmonary medication was found to be as low as
30% among adolescents. (Dekker, 1993).
Evidence shows that reasons for medication non-adherence among asthma patients are complex
and multifold. Factors found in the literature are listed below.
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3.3.6 Patient Related Factors
Age and gender: Many studies have found that age is risk factor for medication non-adherence
and most of them agreed that older age is associated to non-adherent behavior (Jonasson, 1999;
Strunk, 2002). Although some papers found that females were more non-adherent to medication
than males, Jonasson and Strunk found no such difference in their research.
Race and ethnicity: A study on examining differences between white patients and AfricanAmerican patients with asthma found that African-American patients showed poorer medication
adherence compared to white patients. Additionally, white females were found to be nonadherent compared to white males (Willliams, 2007).
Socioeconomic: A study on factors affecting adherence in asthmatic children evaluated
preventive medication use among fifty one children for 1 month using electronic monitoring
device and found that child’s age, family income and parent’s level of education did not affect
medication adherence, but parental stress, forgetting medication or child’s reaction to medication
were reported by parents as the main factors. By comparing the actual usage of medication and
parent’s perspective from a questionnaire, parents were found to report overestimated medication
use (Burgess, Sly et al. 2008).
Sociocultural: A cohort study of elderly asthma patients found that negative attitude towards
inhaled controller medications, family dysfunction, psychological adjustment, and depression are
risk factors for poorer adherence (Krauskopf, 2013). An 18-month study on fill patterns of
underserved children with asthma revealed that filling of controller medication was lower than
prescribed, while rescue medications were filled abundantly. Side effects from medication, low
asthma and medication knowledge was found to be the barrier in this study (Bollinger, 2013).
Disease related: A study found that adherence to asthma medication was affected by
comorbidity, adverse reactions to medications disease severity (Charach, 2008), and long
symptom free period.
Medication related: According to a study on patient preferences for enhancing adherence, too
many pills, side effects, lack of information on the benefits of medication, physician and patient
relationship were reported as a few factors to be tackled (Cascade, 2010). Other factors include
children’s understanding of taking medication (Charach, 2008), regimen complexity, and
frequent doses (Viswanathan, 2012; Morisky, 2008; Battistella, 2016).
Other factors include: lack of transportation, physician and patient relationship (Martin, 2005),
healthcare locations, and disruptions in lifestyle.
The literature on asthma studies shows that the factors influencing medication adherence are
broad and a more thorough understanding is necessary to address this issue. Most studies in the
past have used correlation or regression analysis to find associations between medication
adherence and a variety of factors or predictors appropriate to the population being examined
(Rapoff, 2010). This paper also used correlation and multiple logistic regression analysis to
examine factors affecting medication non-adherence among asthma patients.
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3.3.7 Current Methods to Improve Medication Adherence
Numerous interventions were developed over the years to improve patient’s adherence to
medication such as dosage modification, reminder systems, adherence packaging, drug
education, side effect management, self-monitoring (Chen, 2010), and intervention through
pharmacists, physicians or nurses etc. Some of the current interventions methods are discussed
below:
1. Educating patients to promote medication adherence by healthcare providers:
Explaining the importance and discussing any reluctance to take medications has
been considered as an educational intervention and it is quite successful in most
chronic illnesses (Ratanawongsa, 2013). Attempts to improve adherence through
written education alone turned out to be unfruitful therefore, Nicholoas-English,
DiMatteo and Cascade E, in their respective studies suggested to embrace patient
centered activities that empower them (Nicholas-Green, 2000; DiMatteo,M.R,
2004; Cascade, 2009). These patient-centered activities could be a combination of
written, verbal and other approaches that educate patients on their overall
adherence.
2. Intervention through monitoring patient activity: A randomized clinical study on
Internet-based monitoring of asthma among 300 patients was conducted in the
year 2005. Patients were randomly assigned to three groups monitoring by
specialist, monitoring by general practitioner, and home telemonitoring through
Internet (Intervention group). A 6 month long study concluded that intervention
group of home telemonitoring through internet reported lesser asthma symptoms
during the study period than the other two groups and were found to have better
pulmonary function and quality of life (Rasmussen et al., 2005). Few other studies
reported similar results for Internet based interactive methods among asthma
patients (Jan et al., 2007; Guendelman et al., 2002).
3. Health coaching: Heath coaches are being used in primary care settings to help
patients cope with one or multiple chronic diseases. Medication adherence
counselling and collaborative communication are facilitated by these trained
professionals in clinical settings to improve health outcomes (Thom et al., 2015).
A study on impact of health coaching on medication adherence among patients
with three poorly controlled illnesses, type 2 diabetes, hypertension and or
hyperlipidemia for 12 months found that health coaching significantly increased
medication adherence (10%).
4. Packaging interventions: Blister packs, unit-packaging, pill boxes, unit of dose
packaging and monitored dosage systems are some of the examples of packaging
interventions currently in use to improve medication adherence. Single use
packaging of medications by a professional is called a blister pack, these are
generally recommended for adults with multiple chronic conditions (Mahtani,
2011).
5. Case or illness management for chronic illnesses: Case management services
emerged in 1990s as a strategy to manage and coordinate care using nurses and
other resources to impart knowledge on self-management skills, reduce
readmissions, improve quality, discharge planning, consistency and administer
cost effective care for chronic illnesses (Rosenthal, 2008; Joo, 2014; Berg, 2015).
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Although the definition of case management is ambiguous, the goal for all the
case management services stand the same. Licensed professionals are appointed
as case managers to high risk or patients in need to assistance. Generally,
physician visit reminders, follow up phone calls, health assessment, and planning
depending upon the requirements of the client. These services are designed to
provide safety, efficiency and patient centeredness.
A study by Boyd showed significant reduction in hospitalization rates after 1 year of case
management intervention compared to usual care group of patients (Boyd, 1996).
Woohyun et al, focused on using mobile computing, medical sensors and communication
technology for supportive communication between adolescents with asthma and case
managers, the findings of this study were consistent with literature and has identified the
usefulness of interaction between clinician and patient, successful information exchange
and patient centeredness of case management services (Yoo, 2015).
3.3.8 Strategies to improve medication adherence
Medication adherence is a particularly important health-related behavior for many people faced
with complex therapeutic regimens and/or chronic illnesses. A combination of several simple
strategies, such as more thorough patient instructions, reminders, pill containers, selfmanagement plans and phone follow-up, have been found to improve adherence and treatment
outcomes (De Geest et al. 2006, Haynes et al. 2008). Patient education alone has not been found
to be sufficient to change and sustain adherence to medication (Sabate 2003). Interventions that
focus on the whole person and the therapeutic relationship are needed to improve health
outcomes (Sabate 2003, Maizes et al. 2009).
Many of the interventions though effective are undesirable in many cases as they are expensive,
have low external validity, labor intensive, complicated to carry out, not extremely effective and
can be carried out for small durations only (Bender, 2015). Interventions should be tailor made
for the target population and disease condition as a single intervention cannot be expected to play
an effective role across all patients, establishments and conditions (Burkhart & Sabate, 2003).
Improving medication adherence might be the best investment for tackling chronic conditions,
enhances patient safety and health system effectiveness, reduces poor outcomes and associated
health care costs (Burkhart & Sabate, 2003).
3.3.9 Research gaps
Failure to take asthma medication as prescribed has many consequences, few of which include
poor health, increased healthcare costs, and increased service utilizations. Even though there are
established guidelines for management of asthma such as EPR-3, GINA etc. adherence to asthma
medications have not significantly improved over the years. Services and interventions such as
telemonitoring, asthma health education, self –management education, and case management
services etc. have been set up for improved healthcare outcomes. Case management services
have been established in the 1990s and reduce the gap between patient and healthcare services. A
physician might not be able to dedicate more than his scheduled time for the doubts and concerns
of every patient, due to their busy schedule. Therefore, nurses, healthcare officials and other
trained resources as case managers help bridge the gap between patient and healthcare services,
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encourages self-management of their illnesses, address their concerns and be a continual member
in their healthcare journey.
Understanding factors resulting in medication non-adherence is important to improve medication
adherence behavior in patients and in turn reduce the readmission rates of asthma patients. Large
body of investigations on this topic are available but very few studies attempted to determine the
influence of case management services on medication adherence. Most studies focus on its effect
on reducing hospitalizations and readmissions. Most of the research concerning medication
adherence in asthma is covered in healthcare journals and revolves around finding the factors
only. Therefore, there is a clear gap in the knowledge of the role of case management services in
improving medication adherence behavior for asthma patients.
3.4 Materials and methodology
3.4.1 Objective of the study
In order to develop interventions and improve medication adherence, understanding reasons for
non-adherence is important. The objective of this study is to identify key factors and barriers of
medication non-adherence among Medicaid insured asthma patients and recommends potential
interventions. An additional objective is to propose effective patient selection criteria for
intervention that will improve medication adherence rates.
3.4.2 Subjects
The study population includes Medicaid asthma patients, insured by Insurance company from
January 2015 to December 2016 with maximum of 45 days of enrollment gap from the
insurance, have had taken prescribed asthma controller medication during the study period
(January 2015 to December 2016), and have had one or more hospital claims (Inpatient stay)
with primary or secondary diagnosis of asthma are the subjects in the study.
3.4.2.1 Participant inclusion criteria


Patients with at least one refill of asthma medication and at least one or more hospital
claims of primary or secondary diagnosis of asthma during the study period will be
included.



Patients with a maximum of 45-day enrollment gap with the insurance are considered.

3.4.2.2 Participant exclusion criteria






Patients with interrupted claims data history (<6 months) during the study period.
Medical claim that is not related to asthma treatment (such as an accident, sprain etc.).
Pharmacy claim during the study period for any reason other than asthma medication.
Patient that discontinued insurance with the insurance company during the study period.
Missing invalid data on claims and demographics.
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3.4.3 Dependent variables
The dependent variable for this study is Medication adherence and the Medication Possession
ratio (MPR) will be used to measure medication adherence in this paper. Following is the
formula of MPR.
Total number of days covered
x 100
(Number of days in measurement period) + last fills supply
1. To calculate the numerator, the study period was determined (2 years for this study) and
all the days supply of asthma medication obtained from claims data was summed to get
total number of days covered.
2. The total number of days covered were then divided by the number of days in the study
period plus the last fills days supply and multiplied by 100 to obtain MPR for one patient.
3. If the number was greater than 80% Patient was considered adherent and lesser than 80%
was considered non-adherent.
MPR =

3.4.4 Independent variables
The independent variables include patients’ age, gender, income level(socioeconomic indicator
by zip codes), number of inpatient visits, number of ED visits, number of 30 day and 90 day
readmissions to a facility, type of insurance, and enrollment in case management services.
3.4.5 Selection Criteria for Case management
Effect of case management on medication adherence behavior is an integral part of this study.
Information on the selection criteria for patients to be case managed, procedure that follows, the
role and interaction of case managers with members was documented. Risk utilization reports
consisting of details on frequency of resource utilization, unit cost, and time to event are the
main triggers for selecting potential patients that need case management. Once the patients are
identified they are referred for case management and are contacted by the company for approval
on being case managed.
3.4.6 Data Source:
Data for this study was obtained from software databases namely Microstrategy and EDW data
warehouse used by the insurance provider company. The data comprises of patient information,
medical claims, outpatient claims, and pharmacy claims. Since the study population only consists
of asthma patient’s asthma ICD, procedure and medication codes were used to identify asthma
patients from all the members in the insurance plan.
1. ICD 9 (493.XX) and ICD 10 (J45.XX) codes for asthma. Codes used in the study are
attached as Appendix A.
2. Procedure codes (Attached in Appendix F) of most commonly used resources by asthma
patients. E.g.: Code 94010 for spirometry, including graphic record, expiratory flow rate
measurements. This procedure is commonly used to determine the pulmonary function
among asthma patients. A list of such most common procedures for asthma patients were
created to identify population that used asthma services.
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3. Complete list of asthma medication available in the HEDIS 2015 asthma medication list
is the third component used in obtaining asthma population. Each drug in the HEDIS
medication list has a NDC (National Drug Identifier) number. NDC code is a 10 digit, 3
segment unique identifier for each medication. Labeler, product and trade package are the
3 segments of the identifier number. Medications of drug categories namely short-acting
beta agonists, oral corticosteroids/systemic corticosteroids, inhaled corticosteroids,
combination medications, long-acting beta agonists, leukotriene receptor agonists,
immunomodulators, cromolyn sodium, nedocromil, and methylxanthines were part of the
list and were used to determine the population taking asthma medications. Asthma
medication list by HEDIS is attached as APPENDIX G of this paper.
The combination of all the above three steps that is ICD codes, procedure codes and asthma
medication list are used to identify asthma patients/members in the insurance plan or have
undergone any special procedures or taken medication related to asthma.
3.4.7 Data collection:
(i). Hospital data was collected for demographic information such as age, gender, Zip codes
(indicator of socioeconomic standing of the member), office visits, ED visits, inpatient stay, and
primary care physician. (ii). Economic data such as median household income was not available
for the study. However, this study used the economic indicator data by zip codes provided by the
United States Census Bureau to report median household income. (iii). Medical claims data was
collected to obtain information such as date, place, and type of service, procedure performed,
cost charged and covered per service. (iv). Pharmacy records helped understand the medication
history. It included the following: Name of the medication, day of prescription fills, number of
refill, dosages, medication counts and, duration of medication/ day’s supply. (v). Insurance
information: patients enrolled in case management or any other disease management services,
insurance eligibility for the study period etc. (vi). Interviews with insurance professionals were
conducted to get an idea of types of insurances offered, eligibility criteria for it, and eligibility
criteria to enroll in case management services. (vii). Group interviews were conducted with the
Chief medical affairs director, case managers, and pharmacy officials for clear understanding on
the working techniques in the insurance company. (viii). Telephone interviews were to be
conducted for a random sample of 30-case managed members and 30-non case managed
members originally, but only 12 case managed and 15 non case managed patients participated in
the interviews. The Interview consists of 20 questions related to the member, illness (asthma),
physician, and medication related. The interview procedure and questions are attached in the
appendix A. Each typical phone call lasted 10 minutes.
3.4.8 Hypothesis testing


H1: Levels of control medication adherence for asthma patients will differ by
o Age, gender, number of inpatient visits, number of ED visits, number of 30 day
readmissions to a facility, type of insurance eligibility, and number of medications
will affect prescription adherence.
H2: The insurance company offers several services to help asthmatic patients manage
their illness at their home, such as case management services. Patients who receive these
services will have higher levels of prescription adherence. Levels of prescription
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adherence for asthma patients will differ among Case Management and non-asthmatic
group.
3.4.9 Data Analysis:
Descriptive statistics was conducted on the sample to analyze characteristics of the data. (i) To
address H1a Multivariate logistic regression model was built by backward elimination method to
determine the association of variables of interest such as age, gender, income level, type of
insurance, enrollment in case management services, number of ED visits, number of inpatient
visits, number of 30 day readmissions to a facility with control medication adherence for the
asthma population. (ii) To address H2 a t-test was performed to see if case managed patients
have higher levels of prescription adherence. (iii) Telephone interview results were analyzed to
identify objective measure of medication adherence and point out barriers to medication
adherence with respect to the study population. All the analysis required in the study was
conducted using SAS.
3.5 Results
3.5.1 Sample description
Patient population for this study consists of 687 asthma patients that fulfilled the inclusion
criteria. Of these 687 patients 41 (6%) patients are case managed by the insurance company. A
summary of the descriptive statistics of the study population is shown in the table 2. 16., below.
The average age was 20 years, with the youngest patient being 1 year old and the oldest being 65
years old. Most patients (65%, 449) are considered minors, under the age of 18. 384 (56%) of the
patients were females, while 303 (44%) were male. According to the 2016 U.S Census bureau
income statistics, 75% (517) of the households received $25,000 to $50,000 approximately, per
year.
Table 2. 16. Patient demographics of asthma patients (n=687).
Variable
Age
0-18 years
18-29 years
30-39 years
40-49 years
50-59 years
60-69 years
Gender
Female
Male
Income Level
Less than 25K
Between 25K and 50K

Number (n)

Percent (%)

Cumulative
Frequency

Cumulative
Percent

449
49
64
52
58
15

65.36
7.13
9.32
7.57
8.44
2.18

449
498
562
614
672
687

65.36
72.49
81.8
89.37
97.82
100

384
303

55.9
44.1

384
687

55.9
100

35
482

5.09
70.16

35
517

5.09
75.25
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Variable (Cont’d)

Number (n)
(Cont’d)

Percent (%)
(Cont’d)

165
5
7
2
17
153
87
421

Between 51K and 75K
Between 76K and 100K
Insurance coverage
Behavioral Health
CHIP
Foster Care
Medicaid Expansion
SSI Non-Dual
TANF

24.02
0.73

Cumulative
Frequency
(Cont’d)
682
687

Cumulative
Percent
(Cont’d)
99.27
100

1.02
0.29
2.47
22.27
12.66
61.28

7
9
26
179
266
687

1.02
1.31
3.78
26.06
38.72
100

3.5.2 Medication adherence:
Medication adherence was measured using variable Medication possession ratio for control
medication and rescue medications separately. MPR for rescue adherence and control adherence
are shown in the table 2. 17. below. All MPR values were truncated and do not exceed 100 %.
On an average, asthma patients (n=687) showed 82.3% (SD=26.2) control medication adherence.
546 out of 687 patients took rescue medication during the study period and showed 60%
(SD=34.6) rescue medication adherence.
Table 2. 17. MPR for Control and Rescue medications.
Variables
Mean
Standard Error
Median
Standard Deviation
Range
Minimum
Maximum
Total number of claims
Number of patients
Largest
Smallest
Confidence
Level(95.0%)

MPR for control
adherence (n=687)
82.36
1
100
26.21
91.26
8.74
100
56579
687
100
8.74

Rescue medication
MPR (n=546)
59.82
1.48
60.06
34.58
97.42
2.58
100
32660
546
100
2.58

1.96

2.91

The study population were covered with one of the following type of coverages during the study
period: Temporary assistance for needy families (TANF), Medicaid Expansion, Supplemental
security income Non-dual (SSI Non-Dual), Foster care. Eligibility criteria for each of the
coverages is different and all of them provide low-cost healthcare coverage to Americans falling
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under one or more of the following criteria: people with low income, children, foster care,
families, pregnant women, mental health and substance use disorder, elderly or people with
disabilities. Table 2. 18., shows that 279 members out of the total asthma patients were covered
under TANF are control medication adherent and 142 members do not take their medication as
prescribed. Out of 87 SSI non dual covered patients, 47 are control medication adherent and 40
are non-adherent to control medication.
Table 2. 18. MPR for Control and Rescue medication depending on the type of insurance.
Control medication MPR(less than
80)
142
TANF
40
SSI non-dual
28
Medicaid expansion
2
Foster care
0
CHIP
1
Behavioral Health
213
Total
Coverage

Control Medication MPR (greater
than 80)
279
47
125
15
2
6
474

3.5.3 Multivariate logistic regression for hypothesis #1
Factors associated with control medication adherence were analyzed using backward selection in
multivariate logistic regression. In step 0: age, gender, income level, number of inpatient admits,
number of emergency department visits, number of 30 and 90 day readmissions, case
management status, and type of insurance coverage (i.e., Temporary assistance for needy
families (TANF), Medicaid Expansion, Supplemental security income Non-dual (SSI Non-Dual),
Foster care) were entered into the model. After performing multivariate logistic regression the
following variables were removed from the model (Table 2. 19.).
Table 2. 19. Summary of effects removed in backward elimination

From table 2. 20, it is clear that two types of insurance coverage TANF and SSI-nondual (pvalues=<0.0001) are significant at 0.05 level. Also even though age, male and 30-day
readmissions were not significant at 0.05 level, they were still allowed into the model since their
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coefficients’ directions are consistent with literature (i.e. females are more adherent to
medication than males, older people are less adherent than younger population). Model fit
statistics for the final model is shown in Table 2. 21.
Table 2. 20. Analysis of maximum likelihood.

Table 2. 21. Model fit statistics

The equation for the final model is:

Log (odds of control medication adherence) = 2.0672-0.0121*age-0.2456*male+0.3888*30 day
readmissions-1.1399*TANF-1.5228*SSI-nondual
Table 2. 22. Odds ratio for multivariate logistic regression for asthma patients (n=687).

From Table 2. 22.
(i)

(ii)

It can be seen that patients with TANF and SSI Non-dual coverages tend to be less
adherent to control medication adherence than other coverages (odds of TANF being
adherent is 0.320 times and SSI non dual is 0.218 times lesser than other insurance
types and they are both significant at 0.05 level).
Older patients are less adherent to medication than younger patients (Odds for an
older patient being adherent is 0.988 times less the odds of younger patient [OR
0.988, 95% CI (0.975-1.001)]) this result is not significant at 0.05 level.
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(iii)
(iv)

Men are less adherent to control medication (Odds of male being adherent is 0.782
times less than female being adherent) this result is not significant at 0.05 level.
Patients with 30-day readmissions have higher control medication adherence
compared to patients without readmissions (Odds for patients with 30-day
readmissions being adherent are 1.475 times higher than the odds of patients without
30-day readmissions) this result is not significant at 0.05 level.

Table 2. 22. Testing of global null hypothesis for the multivariate logistic regression analysis.

The overall logistic regression model was highly significant at the 5% significance level as
indicated by the likelihood ratio, Wald and score tests of the global null hypothesis i.e., the
model parameters are significant (Table 2. 22).
Following is a table of Summary for the factors that were retained in the regression model after
backward elimination.
Table 2. 23. Summary for multiple logistic regression.

3.5.4 T- Test case managed and non-case managed adherence for hypothesis #2
In order to address H2, exploring if both control and rescue medication, will differ among case
managed and non-cased managed patients, a t test was performed.
First part in table 2. 24, displays the mean and the standard deviation, and confidence interval of
the means of control medication adherence depending on whether the patient is a case managed
or not. Table 2. 24, shows that the null hypothesis of equal means and equal variance is not
rejected since the p-value is greater than 0.05 (p=0.1655). It can be concluded that control
medication adherence will not differ among case managed and non-case managed patients (pvalue=0.1310, is greater than 0.05 significance level for pooled).
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Table 2. 24. T-test for control medication adherence among (1=case managed and 0= non-case managed
asthma patients)

From table 2. 25. below, since p-value for the test of equality of variances (p-value=0.8936) is
greater than 0.05, the variances are equal and therefore we look at the p-value for pooled section.
It is 0.5424 (greater than 0.05). Therefore, adherence to rescue medication does not seem to
differ among case managed and non-case managed patients.
Table 2. 25. T-test for Rescue medication adherence (1=case managed and 0= non-case managed asthma
patients)
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3.5.5 Telephone interview:
Out of the entire asthma population for the study (n=687), 41 patients are case managed. When
contacted, only 4 of 41 case managed patients participated in the interview. Therefore, case
managed asthma patients outside our main study population (n=687) were also contacted for the
telephone interview. A total of 27 asthma patients (15 non-case managed and 12 case managed
patients) participated in the telephone interview. Demographic, socioeconomic and clinical data
of these patients, obtained from the interview questions are displayed in the table 2. 26. below.
Mean age of this population was 22 years. There were equal number of African American and
Caucasian patients in both case managed (6 Caucasian, 6 African American) and non-case
managed groups (7 Caucasian, 7 African American and 1 not specified). Students were in
majority among the two groups. About 75% patients in both groups were single and had
comorbidities (chronic illnesses other than asthma). More than 80% patients had a primary care
physician (PCP).
Table 2. 26. Interview population (15 non case managed and 12 case managed)
Variables
Age (Mean)
Gender
Male
Female
Asthma severity
Mild
Intermittent
Severe
Ethnicity
African American
Caucasian
Will not specify
Employment status
Unemployed
Employed
Student
Retired
Does not apply
Education
Elementary School
Middle school
High School Graduate
College Graduate
Drop out
Does not apply

Non case managed
(n=15)
24 years

Case managed
(n=12)
22 years

3 (20%)
12 (80%)

7 (58%)
5 (42%)

7 (46.6%)
3 (20%)
5 (33.3%)

5 (41.6%)
4 (33.3%)
3 (25%)

7 (46.6%)
7 (46.6%)
1 (6.6%)

6 (50%)
6 (50%)
0

4 (26.6%)
3 (20%)
6 (40%)
1 (6.6%)
1 (6.6%)

4 (33.3%)
0
7 (58%)
1 (8.3%)
0

4 (26.6%)
2 (13.3%)
3 (20%)
3 (20%)
2 (13.3%)
1 (6.6%)

4 (33.3%)
2 (16.6%)
2 (16.6%)
2 (16.6%)
0
0
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Variables
(Cont’d)
No answer
Marital status
Single
Married
Separated
Divorced
Widowed
Members in the house
4 or less
5 or more
Comorbidities
Yes
No
PCP
Yes
No

Non case managed
(n=15) (Cont’d)
0

Case managed
(n=12) (Cont’d)
2 (16.6%)

12 (80%)
2 (13.3%)
0
1 (6.6%)
0

9 (75%)
1 (8.3%)
1 (8.3%)
0
1 (8.3%)

9 (60%)
6 (40%)

8 (66.6%)
4 (33.3%)

11 (73.3%)
4 (26.6%)

9 (75%)
2 (16.6%)

13 (86.6%)
2 (13.3%)

10 (83.3%)
2 (16.6%)

Following table 2. 27. Shows the yes and no responses of case managed and non-case managed
asthma patients for questions regarding their medications, physician and themselves.
Table 2. 27. Interview questions and responses among non-case managed and case managed asthma
patients (n=27).
Interview questions

Non case managed
(n=15)
Yes
No
11
4 (26.6%)
(73.3%)
6 (40%)
9 (60%)

Case managed (n=12)

12 (80%)
7 (46.6%)
14
(93.3%)

Well informed about asthma medication
Side effects with medication

10
(66.6%)
12 (80%)
2 (13.3%)

Medications not working

5 (33.3%)

Currently taking medications
Control medication even without symptoms
Physician related questions
Taught you to recognize early signs of symptoms
Have an asthma action plan
Showed you how to use an inhaler
Patient related questions
Take medications even during symptomless period

Do not need preventive treatment

6 (40%)
60

Yes
10 (83.3%)

No
2 (16.6%)

5 (41.6%)

7 (58%)

3 (20%)
8 (53.3%)
1 (6.6%)

10 (83.3%)
9 (75%)
12 (100%)

2 (16.6%)
3 (25%)
0

5 (33.3%)

6 (50%)

6 (50%)

3 (20%)
13
(86.6%)
10
(66.6%)
9 (60%)

11 (91.6%)
2 (16.6%)

1 (8.3%)
10
(83.3%)
11
(91.6%)
8 (66.6%)

1 (8.3%)
4 (33.3%)

Forgot to refill
See different PCP every visit

3 (20%)
5 (33.3%)

Too many medicines

2 (13.3%)

Skipped medication due to cost

4 (26.6%)

Lack of transportation

2 (13.3%)

Anybody in the house smoke or drink

1 (6.6%)

Family support

14
(93.3%)

12 (80%)
10
(66.6%)
13
(86.6%)
11
(73.3%)
13
(86.6%)
14
(93.3%)
1 (6.6%)

5 (41.6%)
1 (8.3%)
2 (16.6%)
3 (25%)
1 (8.3%)

7 (58%)
11
(91.6%)
10
(83.3%)
9 (75%)

5 (41.6%)

11
(91.6%)
7 (58%)

12 (100%)

0

Although responses for most of the questions in table 2. 27, above look similar among the two
groups. By inspection, from table 2. 28. below, the average MPR for control and rescue
medication adherence seem a little higher among non-case managed compared to case managed
asthma patients of the interview population.
Table 2. 28. Average control and rescue medication adherence (15 non case managed and 12 case
managed)
Variable
Average Control medication
adherence
Average Rescue medication
adherence

Non case managed

Case managed

30.4

22.83

57.73

16.92

A t-test was performed for three questions from the phone interview list, including 1) Do you
have an asthma action plan?, 2) Do you forget to refill your control medication?, and 3) Do you
see different Primary care physician every visit?. The purpose of this test was to find any
significant difference among the two groups (case managed and non-case managed). Significant
difference was found for the third question- do you see different PCP every visit. Results showed
a significant difference among the responses of case managed and non-case managed asthma
patients (p-value 0.053). Results of the t-test are attached in Appendix E.
3.6 Discussion
From the literature review, it can be concluded that medication adherence is of utmost
importance among patients with chronic illness. Although several guidelines have been laid out,
patients with chronic illnesses tend to derail from taking medications as prescribed. Average
adherence to control medication (measured by electronic devices) was reported to be 50% to
77% by previous studies (Coutts et.al, 1992; Milgrom et.al, 1996; Burgess, 2011). This study
found an average control medication adherence of 82.3% (SD=26.2), while rescue medication
adherence was only 59% (SD=34.6). Rescue medications are only used as needed i.e., in case of
asthma attacks for quick relief. Therefore, focus was placed on control medication adherence.
This study identified five variables that may help explain control medication adherence among
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asthma patients. Two demographic variables, age and gender, one clinical variable, 30 day
readmissions to the hospital, and two types of Medicaid insurance (TANF and SSI Non dual)
remained in the model. Furthermore, only the two types of insurance coverage, TANF (p-value
=<0.0001) and SSI- non dual (p-value =<0.0001) were significant at 0.05 level.
Age and gender are the two demographic factors that have been studied widely in the literature in
association with medication adherence. Age has been found to affect adherence by some
researchers (Jonasson, 1999; Strunk, 2002). Strunk et al. found that for every 2 year increase in
age a child was more likely to be non-adherent to asthma medication. Similar results were found
by another study, adolescents might be at increased risk of non-adherence (Kyngas, 1999).
Conversely, some studies reported that older adults showed better adherence than younger adults
(Tebbi, 1993). In the present study, adherence among older patients although not significant,
found to be less than younger patients [OR=0.988, 95% CI (0.975-1.001)]. The difference in age
might be a risk factor for several reasons such as forgetfulness, unwillingness to take medication
daily, and comorbidities, etc. Number of female asthma patients (n=384) were slightly higher
than males (n=303) in the present study females were more adherent than males. A study by
Lindberg et. al., on medication compliance among asthma patients found similar results i.e., age
and female gender were associated with medication taking behavior (Lindberg, Ekstrom, Moller,
& Ahlner, 2001).
Medication adherence has been reported as a predictor of 30-day hospital readmissions in many
studies (Rosen et al., 2017). Therefore, even though non-significant, 30 day readmissions was
considered in the study since it was consistent with the literature with odds ratio [OR=1.475,
95% CI (0.841-2.589)]. Patients can be admitted or readmitted to the hospital for multiple
reasons ranging from asthma attack, exacerbation or decline in health. These patients are most
definitely given asthma medications upon discharge from the hospital facility. This could be the
reason behind association between patients with 30-day readmissions and medication adherence.
Insurance coverage: TANF and SSI non dual were two types of coverage found to be significant
predictors of control medication adherence. People with TANF and SSI non dual are less
adherent to control medication compared to other types of insurance coverages. TANF stands for
temporary assistance for needy families and SSI non dual stands for supplemental security
income (SSI) non dual. Although TANF supports families with one or more members with
disability, eligibility for TANF is determined by income (Nadel, 2003; Ziliak, 2004). Majority of
the asthma study population was covered under TANF (n=421) and SSI non dual coverages
(n=87). A study to predict risk factors for cost-related medication non-adherence among older
diabetes reported that factors such as out-of-pocket payments for medications and insurance
status contribute to higher risk of medication non-adherence (Zhang et. al, 2014).
Comparing the medication adherence for case and non-case managed patient, results showed that
there was 95% chances that control medication adherence for non-case managed patient would
fall between 80.18 and 84.26. Similarly, there was 95% chances that control medication
adherence for case managed patient would fall between 77.28 and 84.51(Tables 8.1 and 8.2).
Since the upper bound for both groups could be greater than or equal to 80 (the threshold for
medication adherence), these patients will be considered adherent. The t-test concluded that
control medication adherence does not significantly differ among case managed and non- case
managed patients. Similar results for rescue medication adherence were documented from this
study. Although the study hypothesized that case managed population would have better
62

medication adherence than non-case managed asthma patients, the results looked otherwise. One
possible reason could be a small sample size and proportion of patient’s case managed versus
non case managed. The difference in number of case managed (n=41) and number of non-case
managed patients for control medication (n=646), and difference in the number of case managed
(n=35) and non-case managed asthma patients (n=511) for patients taking rescue medications.
The telephone interviews were conducted to collect responses on various questions related to
demographics, socioeconomic status, medications, physicians and specific questions pointing at
factors for non-adherence to asthma medications. For the question, “Did you take asthma
medication without suffering an attack?” 6 out of 15 (40%) of the non-case managed and 5 out of
12 (41.6%) of the non-case managed patients reported yes and a similar question (take control
medications even during symptomless period) later on in the interview yielded different
responses i.e. 66.6% non-case managed and 50% of case managed patients said yes. When
claims data was used to calculate average control and rescue medication adherence among these
patients. The average MPR values were very low (in table 9.3). 4 out of the 5 non case managed
patients that responded yes for “skipped or stopped taking medication because they were not
working” were African Americans and one was Caucasian. 33% of non-case managed and 8% of
case managed patients reported that they see different physician every time even though they had
primary care physician’s assigned to them. About 25% of both groups reported that they skipped
medications due to cost of medication, While 20 % of non-case managed and 41% of case
managed patients reported that they forgot to refill their medications on time. Since the sample
size of the telephone interview respondents is small, it is hard to conclude strongly about the
factors that might affect medication adherence, even though some kind of trend is seen in the
responses. To rectify this, a larger sample group with a face-to-face or a questionnaire to be filled
via email might get better details and more number of respondents.
3.6.1 Ethical considerations
Data will be de-identified and necessary steps such as HIPAA training will be taken to honor the
privacy of patients and their data. Protection of participants will be ensured by taking approval
from Institutional Review Board and submitting needed consent documents. Patients were free to
decline participation in the survey methods. The principles of ethical research practices such as
confidentiality and anonymity will be followed.
3.6.2 Limitations
Limitations of using pharmacy claims data is assumption that a prescription filled is a
prescription consumed. Pharmacy claims data may not reflect stopping medication due to
physician’s orders or change in patient schedules. Sample was not be divided upon the drug
class. Medication possession ratio used to calculate medication adherence for this population has
a few short comings as it only helps calculate consistency and not persistency.
3.6.3 Summary and Conclusion
In conclusion, the two types of insurance coverage (TANF and SSI-non dual) were the only
significant predictors of control medication adherence among the factors considered in this
study. Also, the t-test of the asthma population (n=687) results showed that control and rescue
medication adherence is not significantly different among case managed and non-case managed
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asthma patients. The sample of 687 asthma patients and also the respondents (n=27) of telephone
interview for this study did not provide enough basis to propose an effective selection criteria for
interventions (i.e. case management type of intervention) in order to improve control medication
adherence.
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FINAL CONCLUSION
The asthma population for this study consisted of patients with Medicaid insurance coverage.
Medicaid insurance in principal covers members with low income conditions. Results found that
control medication adherence has no relationship with any type of hospital visit, patients with
rescue medication adherence tend to have lower emergency visits and inpatient admissions.
Patients with more than 4 office visits had better rescue medication adherence but not control
medication adherence. This goes to explain that people might not follow their doctor’s orders on
control medication but are knowledgeable in the use of rescue medication. Even though this
seems like a good practice, it is not since use of rescue medication should be limited and control
medications should be taken as prescribed by the doctor to avoid exacerbations. Further, patients
with TANF and SSI-non dual coverages tend to be less adherent to control medication compared
to other coverages. Also, males and low income patients were found to have emergency
department visits and older lower income patients have more 30 day-readmissions. Even though
the results from the analysis and responses for the interview questions was not enough
information to propose a selection criteria to improve control medication adherence, they
provided clear picture on what needs to be done. Asthma patients need to be educated on the use
of control medication, rather than wait until they have an asthma attack and take rescue
medication for quick relief. Male, older and low income patients should be further studied to
reduce hospital visits and improve medication adherence. It was also found that control and
rescue medication adherence was not significantly different among case managed and non-case
managed patients.
Future Research
In order to identify hospital utilizations in connection with medication adherence, it would be
advisable for future researchers to consider a larger sample with more variables such as patient’s
race/ ethnicity, individual income, medication cost for each claim, employment status, education,
hospital discharge instructions, physician and patient relation, classification of office visits
(scheduled or unscheduled) and detailed analysis of medications (classification, drug classes,
etc.). Above mentioned variables when analyzed similar to this study might lead to predicting
and improving medication adherence for asthmatic patients.
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APPENDIX A: ICD 9 & ICD 10 CODES
ICD 9 codes
493
493
493.1

Asthma
Extrinsic Asthma
Intrinsic Asthma
Chronic Obstructive
Asthma
Other Forms of Asthma
Exercise Induced
Bronchospasm
Cough Variant Asthma
Unspecified Asthma

493.2
493.8
493.81
493.82
493.9
ICD 10 codes
J45
J45.2
J45.20
J45.21
J45.22
J45.3
J45.30
J45.31
J45.32
J45.4
J45.40
J45.41
J45.42
J45.5
J45.50
J45.51
J45.52
J45.9
J45.90
J45.901
J45.902
J45.909
J45.99
J45.990
J45.991
J45.998

Asthma
Mild Intermittent Asthma
Mild Intermittent Asthma, Uncomplicated
Mild Intermittent Asthma with (Acute) Exacerbation
Mild Intermittent Asthma with Status Asthmaticus
Mild Persistent Asthma
Mild Persistent Asthma, Uncomplicated
Mild Persistent Asthma with (Acute) Exacerbation
Mild Persistent Asthma with Status Asthmaticus
Moderate Persistent Asthma
Moderate Persistent Asthma, Uncomplicated
Moderate Persistent Asthma with (Acute) Exacerbation
Moderate Persistent Asthma with Status Asthmaticus
Servere Persistent Asthma
Servere Persistent Asthma, Uncomplicated
Servere Persistent Asthma with (Acute) Exacerbation
Servere Persistent Asthma with Status Asthmaticus
Other and Unspecified Asthma
Unspecified Asthma
Unspecified Asthma with (Acute) Exacerbation
Unspecified Asthma with Status Asthmaticus
Unspecified Asthma, Uncomplicated
Other Asthma
Exercise Induced Bronchospasm
Cough Variant Asthma
Other Asthma
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APPENDIX B: NON-ASTHMATIC GROUP TABLES
Non-asthmatic group diagnosis
Diagnosis
ABDOMINAL PAIN, UNSPECIFIED SITE

Count
of
Member
ID
1

Count of Actual Admission Date
1

AC CHRN COMB SYSTOLIC AND DIASTOL CHF

1

1

ACUT MI OTH INF WALL INIT EPIS CARE

1

1

ACUT MI SUBNDOCRDL INFARCT INIT EOC

1

1

ACUTE CHRON SYSTOLIC HEART FAILURE

1

1

ACUTE CHRONIC RESP FAIL W/HYPOXIA

1

1

ACUTE EMBO THROMBOS RT FEMORAL VEIN

1

1

ACUTE KIDNEY FAILURE UNSPECIFIED

2

2

AGRANULOCYTOSIS SEC TO CANCER CHEMO

1

1

ALCOHOL USE UNS W/UNS ALC-INDUC D/O

1

1

ALCOHOLIC GASTRITIS WITH HEMORRHAGE

1

1

ALCOHOLIC HEPATIC FAILURE W/O COMA

2

2

ALTERED MENTAL STATUS UNSPECIFIED

2

2

ASPERGILLOSIS

2

2

ASPERGILLOSIS UNSPECIFIED

1

1

ATHSC NATV ART EXT REST PAIN BIL

1

1

ATHSC NATV ART EXT W/GANGREN LT LEG

1

1

BENIGN NEOPLASM COLON UNSPECIFIED

1

1

BENIGN NEOPLASM OF RIGHT OVARY

1

1

BILIARY ACUTE PANCREATITIS

1

1

BIPOLAR CURR DEPRESS SEV W/O PSYCH

1

1

BIPOLAR CURR DEPRESS SEV W/PSYCH

1

1

BIPOLAR CURR DEPRESSED MILD/MOD UNS

2

2

BIPOLAR DISORDER UNSPECIFIED

1

1

BIPOLAR II DISORDER

1

1

CELLULITIS AND ABSCESS OF MOUTH

1

1

CELLULITIS&ABSC UPPER ARM&FOREARM

1

1

CELLULITIS&ABSCESS LEG EXCEPT FOOT

1

1

CELLULITIS&ABSCESS OTHER SPEC SITE

1

1

CEREB INFARCT EMBO RT ANT CEREB ART

1

1

CEREBRAL INFARCTION UNSPECIFIED

1

1

CHF UNSPECIFIED

1

1

CLOSED FRACTURE OF SHAFT OF HUMERUS

1

1

COPD WITH ACUTE EXACERBATION

2

2

CORD AROUND NECK-COMPRS DEL

1

1

CRITICAL ILLNESS MYOPATHY

1

1

CUTANEOUS ABSCESS LEFT UPPER LIMB

1

1
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CUTANEOUS ABSCESS OF NECK

1

1

DECR FETAL MOVEMENTS UNS TRI NA/UNS

1

1

DISORDER OF BRAIN UNSPECIFIED

1

1

DISPLACEMENT INSULIN PUMP INITIAL

1

1

DISPLCMT LUMBAR DISC W/O MYELOPATHY

1

1

DVTRCLI LG INT NO PERF/ABSC W/O BL

1

1

EMBOLISM THROMBOSIS ART UP EXTREM

1

1

EPILEPSY UNS NOT INTRACT W/O SE

1

1

ESOPHAGEAL REFLUX

1

1

FIRST DEG PERINEAL LAC DUR DELIV

1

1

FX UNS PRT NCK RT FEM INIT CLOS

1

1

HB-SS DISEASE WITH CRISIS

7

7

HB-SS DISEASE WITH CRISIS UNS

12

12

HEMIPLG FLW CEREB INFARCT LT N-DOM

1

1

HEMPLG OTH NTRM INTRCRN HEM L N-DOM

1

1

IMMUNE THROMBOCYTOPENIC PURPURA

2

2

INF&INFLAM REACT INT ORTH DEVICE

1

1

INTEST ADHES W/OBST POSTPROC-INFECT

1

1

INTESTINAL INF DUE OTH ORGANISM NEC

1

1

LABOR AND DEL COMP FETAL STRESS UNS

1

1

LAC NO FB LT F WALL THOR NO PEN INT

1

1

MAJ DEPRESS D/O RECURRENT MOD

1

1

MAJ DEPRESS D/O SINGLE EPIS UNS

4

4

MAJ DEPRESS RECURR SEV W/O PSYCH

4

4

MAJ DEPRESS RECURR SEV W/PSYCH SX

1

1

MAJOR DEPRESSIVE D/O RECURRENT UNS

2

2

MISSED ABORTION

1

1

MORBID SEV OBESITY ALVEOLR HYPOVENT

1

1

MULTIPLE SCLEROSIS

1

1

MYCOPLASMA INFECTION UNSPECIFIED

1

1

NONINFECTIVE GE AND COLITIS UNS

1

1

NON-ST ELEVATION MYOCARDIAL INFARCT

1

1

NONTRAUM IC HEMORR HEMISPH SUBCORT

1

1

NORMAL DELIVERY

2

2

OPEN WND FOREHEAD W/O MENTION COMP

1

1

OPIOID DEPENDENCE WITH WITHDRAWAL

1

1

OTH COMPS DUE INTRL JOINT PROSTH

1

1

OTH CURRENT MATERNAL CCE ANTEPARTUM

1

1

OTH CURRENT MATERNAL CCE W/DELIVERY

2

2

OTH MECH COMP INSULIN PUMP INITIAL

1

1

OTH SPEC ABNORMAL UTERINE VAG BLEED

1

1

OTH SPEC DIAB KETOACIDOSIS NO COMA

1

1

OTHER CHEST PAIN

1

1
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OTHER CONVULSIONS

1

1

OTHER GRAM-NEGATIVE SEPSIS

2

2

OTHER NEUTROPENIA

1

1

OTHER POSTOPERATIVE INFECTION NEC

1

1

OTHER SPEC REHABILITATION PROCEDURE

1

1

OTHER SPECIFIED SEPSIS

1

1

PARALYTIC ILEUS

1

1

PARANOID SCHIZOPHRENIA

6

6

PERIAPICAL ABSCESS WITHOUT SINUS

1

1

PERIPHERAL VASCULAR DISEASE UNS

1

1

PNEUMOCOCCAL PNEUMONIA

1

1

PNEUMONIA UNSPECIFIED ORGANISM

5

5

PNEUMONIA, ORGANISM UNSPECIFIED

1

1

POISN OTH RX MEDS BIO SUBS ACC INIT

1

1

POISON OTH OPIOIDS ACC INITIAL ENC

1

1

POISONING BY OPIUM , UNSPECIFIED

1

1

POST-TERM PREGNANCY

1

1

PRE-EXISTING DM TYPE 2 PREG 3RD TRI

1

1

PREMATURE RUPTURE MEMB PG DELIV

1

1

PREV C/S DEL DEL W/WO ANTPRTM COND

3

3

RADICULOPATHY LUMBAR REGION

1

1

SALPINGITIS AND OOPHORITIS UNS

1

1

SCHIZOAFFECTIVE D/O BIPOLAR TYPE

2

2

SCHIZOPHRENIA UNSPECIFIED

2

2

SEPSIS UNSPECIFIED ORGANISM

1

1

SEVERE PRE-ECLAMPSIA, WITH DELIVERY

1

1

SLTR-HARIS II FX LW LT FEM CLO

1

1

STREP B CARR STATE COMP CHILDBIRTH

1

1

SYNOVIAL CYST OF POPLITEAL SPACE

1

1

SYSTEMIC LUPUS ERYTHEMATOSUS

1

1

THROMB VASC PROSTH DEVC GRAFT INIT

1

1

TYPE 2 DM W/FOOT ULCER

2

2

UNS DISLOC RT ULNOHUMERAL JNT INIT

1

1

UNS FX SHFT LT RADIUS INIT OPN I/II

1

1

UNS NONINF GASTROENTERIT&COLITIS

1

1

UNSPEC HEMORRHAGE GI TRACT

1

1

UNSPEC HTN HEART DISEASE W/HF

2

2

UNSPECIFIED ABDOMINAL PAIN

1

1

UNSPECIFIED ACUTE APPENDICITIS

1

1

UNSPECIFIED ANEMIA

1

1

UNSPECIFIED CONSTIPATION

1

1

UNSPECIFIED ESSENTIAL HYPERTENSION

1

1

UNSPECIFIED INTESTINAL OBSTRUCTION

1

1
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UNSPECIFIED SEPTICEMIA

2

2

UNSPECIFIED URETHRAL STRICTURE

1

1

UTI SITE NOT SPECIFIED

3

3

VENTRICULAR FIBRILLATION

1

1

179

179

Grand Total

Cluster history of non-asthmatic group
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Appendix C: SCATETRPLOT FOR CORRELATION ANALYSIS
Scatterplot for correlation between emergency department visits, inpatient admissions, 30 day
readmissions, 90 day readmissions and control medication adherence
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Scatterplot for correlation between emergency department visits, inpatient admissions, 30 day
readmissions, 90 day readmissions and rescue medication adherence
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APPENDIX D: REGRESSION ANALYSIS
Correlation matrix between the independent variable

Scatterplot of the correlation matrix
Scatter Plot Matrix
Male

Income_level

Income_level

Male

Age

Age
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Control medication with age, gender and income.

Emergency visits with age, gender and income

Inpatient Admits with age, gender and income

30 day readmission with age, gender and income
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90 day readmission with age, gender and income
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APPENDIX E: TELEPHONE INTERVIEW
Telephone interview Procedure and Questions

Plan:




2 pilot Interviews to track duration
Reduce or rephrase questions depending on this
Sample size for interviews: 60 (30 case managed/ 30 without it)

Case manager randomly picks members from asthma population. Introduces herself.
1. Are you (the person we intended to call)? May I confirm your/ your child’s age and
gender?
2. Have you ever been diagnosed for asthma? Yes, continue. If not end the call
3. What category of asthma do you have? (mild/intermittent/severe)
4. Race/ ethnicity
5. Employment status/ education
6. Marital status/ family members
7. Comorbidities?
8. Do you have a PCP?
9. Are you case managed or do you take any such services provided by the insurance
company?
10. (IF YES for q.9) Rate case management or disease management services provided to you
by the insurance company
11. Do you know about the transportation facility provided by the insurance company?
12. During the past three months how many asthma attacks have you had? And how long did
they last (dash minutes, dash hours, dash days, dash weeks)?
Medication related
13. Are you currently taking any medications? What are they? How often?
14. In the past 3 months have you taken prescription asthma medicine?
15. In the past 3 months did you take asthma medication when you did not have an asthma
attack? Or on regular schedule as by the doctor
Physician related
16. Has a doctor ever taught you to recognize early signs of symptoms of an asthma episode?
What to do during an asthma episode or prevent an attack?
17. Do you have an asthma action plan? How long ago did you get it?
18. Did a health professional show you how to use an inhaler?

Patient related
19. Let me know if the following are reasons for non-adherence?
 Take control medication even during symptomless period?
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How well informed do you feel about your health and medication (asthma
education/ Uncertain how to use medication/ Uncertain when to use medication)
Side effects with asthma medication
Rx wasn’t working/ Skipped or stopped taking a medicine because you didn't
think it was working?
Don’t need the ICS/ Does not need preventive treatment
Forgetting to take medication/ did not refill on time/ ran out of medication/ not
had medicine with you when it was time to take it?
Stopped taking medication
See different provider each visit (PCP)
Number of prescription medications (Complicated regimen/ Taking medicines
more than once a day is inconvenient.)
Skipped, stopped, not refilled, or taken less medicine because of the cost? /
coverage for prescription medication
Lack of transportation
Do you or anybody in your home smoke/ drink alcohol?
Family support

t-test results for:
Asthma action plan
Method
Pooled
Satterthwaite
Cochran

Method
Folded F

Variances
Equal
Unequal
Unequal

DF
25
24.754

t Value
1.5
1.52
1.52

Pr > |t|
0.1473
0.1416
0.1541

Equality of Variances
Num DF Den DF
F Value
14
11
1.3

Pr > F
0.6671

.

Forgot to refill medication
Method
Pooled
Satterthwaite
Cochran

Method
Folded F

Variances
Equal
Unequal
Unequal

DF
25
20.924

t Value
1.21
1.18
1.18

Pr > |t|
0.2364
0.2499
0.2599

Equality of Variances
Num DF Den DF
F Value
11
14
1.55

Pr > F
0.4373

.
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Primary casre phyician
Method
Pooled
Satterthwaite
Cochran

Method
Folded F

Variances
Equal
Unequal
Unequal

DF
25
22.865

t Value
1.92
2.04
2.04

Pr > |t|
0.0659
0.053
0.0622

Equality of Variances
Num DF Den DF
F Value
14
11
3.09

Pr > F
0.0672

.
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APPENDIX F: ASTHMA PROCEDURES & CODES
Asthma procedure codes and description
Codes
94010
94011
94012
94013
94014
94015
94016
94060
94070
94150
94375
94620
94640
94664
94760
94761
94762
A4614
J7611
J7612
J7613
J7614
J7626
J7627
J7644
J7645
S8096
S8097
S8110
S9441
J7620
J2357
J2810
J7609
J7610

Asthma procedure code description
Spirometry: FVC, VC with or without MVV
Up to 2 years old Spirometry
2 years Spirometry w/dilator
2 years lung volumes
Patient recoded spirometry
Patient recorded spirometry
Review patient spirometry
Evaluation of wheezing
Evaluation of wheezing
Vital capacity requires hook up spirometry
Respiratory flow volume loop
Pulmonary stress testing
Pressurized or non-pressurized inhalation treatment
Demonstration and/or evaluation of patient utilization of nebulizer, metered dose
Noninvasive ear or pulse oximetry for oxygen saturation; single determination
Noninvasive ear or pulse oximetry for oxygen saturation; multiple determination
Noninvasive ear or pulse oximetry by continuous overnight monitoring
Peak expiratory flow rate meter handheld
Albuterol, inhalation solutions, administered through DME, concentrated form, 1mg
Levalbuterol, inhalation solution, administered through DME, concentrated form,
0.5mg
Albuterol, inhalation solution, administered through DME, unit dose, 1mg
Xopenex: Levalbuterol, inhalation solution, administered through DME
Budesonide inhalation solution non compounded up to 0.5 mg
Budesonide inhalation solution compounded up to 0.5 mg
Atrovent: Ipratropium bromide, inhalation solution administered through DME
Ipratropium bromide inhalation solution
Portable peak flow meter
Asthma Kit
Peak expiratory flow rate (physician services)
Asthma education
Albuterol all formulations inhalation
Omalizunab
Theophilline
Albuterol all formulations inhalation
Albuterol all formulations inhalation
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APPENDIX G: IRB APPROVAL
IRB Approval letter
ACTION ON PROTOCOL APPROVAL REQUEST
TO:

Isabelina Nahmens

Mechanical and Industrial Engineering
FROM:

Dennis Landin

Chair, Institutional Review Board
DATE: November 29, 2016
RE:

IRB# 3722

Institutional Review Board Dr. Dennis Landin, Chair 130 David Boyd Hall Baton Rouge, LA 70803 P:
225.578.8692
F: 225.578.5983
irb@lsu.edu | lsu.edu/irb
TITLE:

Evaluating Asthma Care from Hospital to Home to prevent Hospital Readmissions

New Protocol/Modification/Continuation: New Protocol
Review type: Full

Expedited X Review date: 6/15/2016

Risk Factor: Minimal X
Approved

X

Uncertain

Greater Than Minimal_

Disapproved

Approval Date: 11/29/2016

Approval Expiration Date: 11/28/2017

Re-review frequency: (annual unless otherwise stated)
Number of subjects approved: N/A
LSU Proposal Number (if applicable):
Protocol Matches Scope of Work in Grant proposal: (if applicable)
By: Dennis Landin, Chairman
PRINCIPAL INVESTIGATOR: PLEASE READ THE FOLLOWING –
Continuing approval is CONDITIONAL on:
Adherence to the approved protocol, familiarity with, and adherence to the ethical standards of the
Belmont Report, and LSU's Assurance of Compliance with DHHS regulations for the protection of
human subjects*
Prior approval of a change in protocol, including revision of the consent documents or an increase in the
number of subjects over that approved.
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Obtaining renewed approval (or submittal of a termination report), prior to the approval expiration date,
upon request by the IRB office (irrespective of when the project actually begins); notification of project
termination.
1. Retention of documentation of informed consent and study records for at least 3 years after the study ends.
2. Continuing attention to the physical and psychological well-being and informed consent of the individual
participants, including notification of new information that might affect consent.
3. A prompt report to the IRB of any adverse event affecting a participant potentially arising from the study.
4. Notification of the IRB of a serious compliance failure.
5. SPECIAL NOTE: When emailing more than one recipient, make sure you use bcc.
*All investigators and support staff have access to copies of the Belmont Report, LSU's Assurance with DHHS,
DHHS (45 CFR 46) and FDA regulations governing use of human subjects, and other relevant documents
in print in this office or on our World Wide Web site at http://www.lsu.edu/irb
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spring 2014, she was admitted to Louisiana State University, Baton Rouge, Louisiana, USA, to
pursue her master’s degree in Industrial Engineering. She was employed by Mr. Terry Grier as
Graduate Assistant for Facility Services and started working towards her degree under the
guidance of Dr. Isabelina Nahmens. Ms. Nittala expects to receive the degree of Master of
Science in Industrial Engineering (MSIE) in December 2017.
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